Dementia

Last updated

Dementia
An old man diagnosed as suffering from senile dementia. Colo Wellcome L0026689.jpg
1896 lithograph of a man with dementia
Specialty Neurology, psychiatry, Neuropsychiatry
Symptoms Decreased ability to think and remember, emotional problems, problems with language, decreased motivation, general decline in cognitive abilities [1]
Complications Malnutrition, pneumonia, inability to perform self-care tasks, personal safety challenges, fractures from falls. [2]
Usual onsetVaries, usually gradual [1]
DurationVaries, usually long term [1]
Causes Neurodegeneration, vascular disease, stroke, traumatic brain injuries [1]
Risk factors Several across the life course (e.g. less education, hearing loss, vision loss, physical inactivity, obesity, high cholesterol, hypertension, diabetes, smoking, excessive alcohol consumption, social isolation, air pollution, traumatic brain injury, depression) [3]
Diagnostic method Clinical assessment, cognitive testing (mini–mental state examination), [4] and imaging
Differential diagnosis Delirium, depression, hypothyroidism [5]
PreventionAddressing risk factors throughout the life course, e.g. preventing, reducing or treating hearing and vision loss, depression, head injury and vascular risk factors (e.g. cholesterol, diabetes), decreasing smoking, and maintaining physical activity and cognitive stimulation [3]
TreatmentVaries but supportive care is given [1]
Medication Varies depending on the type and stage, most medications have a small benefit [6]
Prognosis Varies, dementia is a life limiting condition and life expectancy is usually shortened
Frequency57 million (2021) [1]
Deaths1.62 million dementia-related deaths (2019) estimated to increase to 4.91 million by 2050 [7]

Dementia is a syndrome, often associated with neurodegenerative diseases such as Alzheimer's, and characterized by a general decline in cognitive abilities that affects a person's ability to perform everyday activities. [8] This typically involves problems with memory, thinking, behavior, and motor control. [1] Aside from memory impairment and a disruption in thought patterns, the most common symptoms of dementia include emotional problems, difficulties with language, and decreased motivation. [1] The symptoms may be described as occurring in a continuum over several stages. [9] Dementia is an incurable, progressive neurocognitive disorder, with varying degrees of severity (mild to major) and many forms or subtypes. [10] [11] The condition has a significant effect on the individual, their caregivers, and their social relationships in general. [1] Dementia is not the same as age-related decline in cognition and memory, with no change in intelligence. [12]

Contents

The most common form of dementia is Alzheimer's. Dementia can be caused by brain injuries and stroke. [1] It has also been described as a spectrum of disorders with subtypes of dementia based on which known disorder caused its development, such as Parkinson's disease for Parkinson's disease dementia, Huntington's disease for Huntington's disease dementia, vascular disease for vascular dementia, HIV infection causing HIV dementia, frontotemporal lobar degeneration for frontotemporal dementia, Lewy body disease for dementia with Lewy bodies, and prion diseases. [13] Subtypes of neurodegenerative dementias may also be based on the underlying pathology of misfolded proteins, such as synucleinopathies and tauopathies. [13] The coexistence of more than one type of dementia is known as mixed dementia. [14]

Diagnosis is usually based on history of the illness and cognitive testing with imaging. Imaging can help to determine the dementia subtype, and to exclude other causes. Blood tests are usually taken to rule out other possible reversible causes such as hypothyroidism (an underactive thyroid). [12]

Although the greatest risk factor for developing dementia is aging, dementia is not a normal part of the aging process; many people aged 90 and above show no signs of dementia. [12] Risk factors, diagnosis and caregiving practices are influenced by cultural and socio-environmental factors. [15] Several risk factors for dementia, such as smoking and obesity, are modifiable by lifestyle changes. Screening the general older population for the disorder is not seen to affect the outcome. [16]

Dementia is currently the seventh leading cause of death worldwide and has 10 million new cases reported every year (approximately one every three seconds). [1] In the UK it is the leading cause of death. [17] It is one of the main causes of disabilities in those aged over 65. [18] There is no known cure for dementia. [19] Acetylcholinesterase inhibitors such as donepezil are often used in some dementia subtypes and may be beneficial in mild to moderate stages, but the overall benefit may be minor. There are many measures that can improve the quality of life of a person with dementia and their caregivers. Cognitive behavioral therapy may give some benefit for treating the associated symptoms of depression. [20]

Signs and symptoms

The signs and symptoms of dementia may vary depending on the underlying subtype, but may be grouped into three areas: cognitive, neuropsychiatric (also known as behavioral and psychological), and physical. [3]

The cognitive symptoms of dementia relate to the area of the brain affected. Typically this includes memory plus one other cognitive region. [6] The most commonly affected areas of brain function include memory, language, attention, problem solving, and visuospatial function affecting perception and orientation. Signs of dementia include wandering, and getting lost in a familiar neighborhood, using unusual words to refer to familiar objects, forgetting the name of a close family member or friend, forgetting old memories, forgetting to pay bills, and being unable to complete tasks independently. [6] [21] The symptoms progress at a continuous rate over several stages, and they vary across the dementia subtypes. [22] [9] Most types of dementia are slowly progressive with some deterioration of the brain well established before signs of the disorder become apparent.

The behavioral symptoms can include agitation, restlessness, inappropriate behavior, sexual disinhibition, and verbal or physical aggression. [6] Behavioral symptoms in dementia are thought to be often due to unmet needs or untreated physical symptoms. [23] [24] Many of these symptoms may be improved by non-pharmacological measures such as appropriate exercise and empowering carers. [25]

Psychological symptoms can include depression, hallucinations (most often visual), delusions, apathy, and anxiety. [6] Also common are personality changes with the progression of dementia, such as increases in neuroticism (negativity), and a decline in conscientiousness. [26]

Signs of dementia may include changes in gait, falls, repetitive movements, parkinsonism, or seizures. [6] In later stages, incontinence both urinary and fecal may be prominent features that can prove challenging for both the person affected and the caregiver. [27] Dementia can also affect the person's eating and drinking, often causing swallowing issues and weight loss that worsen as the illness progresses to later stages. [28] Pain can also affect people with dementia, potentially as many as 79.6% of people with dementia in nursing homes may experience pain. However pain can be difficult to assess as people with dementia may be unable to communicate this verbally and instead it may manifest as behavioral symptoms. [29]

Other health conditions as comorbidities may be present; some such as high blood pressure or diabetes, are associated with a risk for dementia, and others such as depression, and anxiety are associated with dementia itself. [30] There is also an increased prevalence of sarcopenia (muscle loss) and frailty. [31]

Stages

The course of dementia is often described in three major stages (early, middle, and late) that show a pattern of progressive cognitive and functional impairment. [32] The Global Deterioration Scale uses seven stages in the development of dementia, with mild dementia only appearing as stage 4. [33] [34]

Other scales used are the Brief Cognitive Rating Scale (BCRS), [35] Clinical Dementia Rating (CDR), and the Functional Assessment Staging Tool (FAST). [33] [36] The BCRS is a quick assessment that coincides with the GDS. It uses five axes in assessment – concentration, memory (recent and past), orientation, functioning and self-care. [35] FAST places more emphasis on functioning in daily living. [33] CDR evaluates six main areas including memory, judgement, problem-solving, and personal care. [33] The mini–mental state examination (MMSE) is an often used test to screen cognitive ability. [33] RUDAS, the Rowland Universal Dementia Assessment Scale, is a short dementia screening test for use in diverse multi-ethnic communities designed to overcome language and cultural differences. [37]

Pre-dementia

Pre-dementia includes a pre-clinical stage, before the onset of symptoms, and prodromal the early clinical symptoms.

Pre-clinical

Sensory dysfunction, most notably the loss of the sense of smell (anosmia) is claimed for the pre-clinical stage, which may precede the first clinical signs of dementia by up to ten years. [9] [38] Anosmia is associated with depression and a loss of appetite leading to poor nutrition. [39] It is suggested that anosmia may come about because the olfactory epithelium is exposed to the environment, and the lack of blood–brain barrier protection allows toxic elements to enter and cause damage to the chemosensory networks. [9]

Prodromal

Pre-dementia states considered as prodromal are mild cognitive impairment (MCI) and mild behavioral impairment (MBI). [40] Signs and symptoms at the prodromal stage may be subtle, and the early signs often become apparent only in hindsight. [41] In mild cognitive impairment, that progresses to a dementia subtype, changes in the person's brain have been happening for a long time, but the symptoms are just beginning to appear. These problems, however, are not severe enough to affect daily function. If and when they do, the diagnosis becomes one of a dementia subtype, such as minor neurocognitve disorder of Lewy body disease, for example. The person may have some memory problems and trouble finding words, but they can solve everyday problems and competently handle their life affairs. [42] During this stage, it is ideal to ensure that advance care planning has occurred to protect the person's wishes. Advance directives exist that are specific to people living with dementia. [43] These can be particularly helpful in addressing the decisions related to feeding which come with the progression of the illness. Mild cognitive impairment has been relisted in both DSM-5 and ICD-11 as "mild neurocognitive disorders", i.e. milder forms of the major neurocognitive disorder (dementia) subtypes. [44] But MCI does not always progress to dementia, and sometimes symptoms resolve. [12]

Kynurenine is a metabolite of tryptophan that regulates microbiome signaling, immune cell response, and neuronal excitation. A disruption in the kynurenine pathway may be associated with the neuropsychiatric symptoms and cognitive prognosis in mild dementia. [45] [46]

Early

In the early stage of dementia, symptoms become noticeable to other people. In addition, the symptoms begin to interfere with daily activities, and will register a score on a mini–mental state examination (MMSE). MMSE scores are set at 24 to 30 for a normal cognitive rating and lower scores reflect severity of symptoms. The symptoms are dependent on the type of dementia. More complicated chores and tasks around the house or at work become more difficult. The person can usually still take care of themselves but may forget things like taking pills or doing laundry and may need prompting or reminders. [47]

The symptoms of early dementia usually include memory difficulty, but can also include some word-finding problems, and problems with executive functions of planning and organization. [48] Managing finances may prove difficult. Other signs might be getting lost in new places, repeating things, and personality changes. [49]

In some types of dementia, such as dementia with Lewy bodies and frontotemporal dementia, personality changes and difficulty with organization and planning may be the first signs. [50]

Middle

As dementia progresses, initial symptoms generally worsen. The rate of decline is different for each person. MMSE scores between 6 and 17 signal moderate dementia. For example, people with moderate Alzheimer's dementia lose almost all new information. People with dementia may be severely impaired in solving problems, and their social judgment is often impaired. They cannot usually function outside their own home, and generally should not be left alone. They may be able to do simple chores around the house but not much else, and begin to require assistance for personal care and hygiene beyond simple reminders. [51] In neurodegenerative demantias a lack of insight into having the condition will become evident. [52]

Late

People with late-stage dementia typically turn increasingly inward and need assistance with most or all of their personal care. 24 hour supervision to meet basic needs and ensure personal safety is usually needed. If left unsupervised, they may wander or fall; may not recognize common dangers such as a hot stove; or may not realize that they need to use the bathroom and become incontinent. [42] They may not want to get out of bed, or may need assistance doing so. Commonly, the person no longer recognizes familiar faces. They may have significant changes in sleeping habits or have trouble sleeping at all. [51]

Changes in eating frequently occur. Cognitive awareness is needed for eating and swallowing and progressive cognitive decline results in eating and swallowing difficulties. This can cause food to be refused, or choked on, and help with feeding will often be required. [53] For ease of feeding, food may be liquidized into a thick purée. They may also struggle to walk, particularly among those with Alzheimer's disease. [54] [55] [56] In some cases, terminal lucidity, a form of paradoxical lucidity, occurs immediately before death; in this phenomenon, there is an unexpected recovery of mental clarity. [57]

Types

Most types of dementia including Alzheimer's (the most common), Lewy body dementias, and frontotemporal dementia are neurodegenerative diseases, and protein misfolding is a cardinal feature of these. [58] The next most common type of dementia after Alzheimer's is vascular dementia, a cerebrovascular disease. These are the main primary types. Secondary types of dementia are secondary to a pre-existing condition, such as Huntington's dementia secondary to Huntington's disease, and HIV-associated dementia secondary to HIV. Different dementias have different causes and risk factors. [14] But all types are characterized by loss of neurons, and consequent functioning. [8] Pseudodementia is a term that is sometimes used to describe dementia-like symptoms as a dementia secondary to psychiatric conditions especially to depression. [59]

Alzheimer's disease

Brain atrophy in severe Alzheimer's Alzheimers brain.jpg
Brain atrophy in severe Alzheimer's

Alzheimer's disease also called Alzheimer's dementia, accounts for 60–70% of cases of dementia worldwide. The most common symptoms of Alzheimer's disease are short-term memory loss and word-finding difficulties. Trouble with visuospatial functioning (getting lost often), reasoning, judgment and insight fail. Insight refers to whether or not the person realizes they have memory problems.

The part of the brain most affected by Alzheimer's is the hippocampus. Other parts that show atrophy (shrinking) include the temporal and parietal lobes. Although this pattern of brain shrinkage suggests Alzheimer's, it is variable and a brain scan is insufficient for a diagnosis.

Little is known about the events that occur during and that actually cause Alzheimer's disease. This is due to the fact that, historically, brain tissue from people with the disease could only be studied after the person's death. Brain scans can now help diagnose and distinguish between different kinds of dementia and show severity. These include magnetic resonance imaging (MRI), CT scans, and positron emission tomography (PET) using Pittsburgh compound B. However, it is known that one of the first aspects of Alzheimer's disease is overproduction of amyloid. Extracellular amyloid plaques, consisting of amyloid beta (Aβ) peptides, and intracellular neurofibrillary tangles that are formed by hyperphosphorylated tau proteins, are the hallmarks of Alzheimer's. [60] Amyloid causes inflammation around the plaques, and excessive inflammation leads to changes in the brain that cannot be controlled, leading to the symptoms of Alzheimer's. [61]

Flotillin has been proposed as a potential biomarker for detecting early Alzheimers in CSF or blood. [62] A finger-prick blood sample for the diagnosis of early AD has been developed using p-tau 217 as biomarker. [63]

Vascular dementia

Risk factors and signs and symptoms of vascular dementia Fcvm-08-803169-g0001.jpg
Risk factors and signs and symptoms of vascular dementia

Vascular dementia accounts for at least 20% of dementia cases, making it the second most common type. [64] It is caused by disease or injury affecting the blood supply to the brain, typically involving a series of mini-strokes. Symptoms depend on where in the brain the strokes occurred and whether the blood vessels affected were large or small. [51] Repeated injury can cause progressive dementia over time, while a single injury located in an area critical for cognition such as the hippocampus, or thalamus, can lead to sudden cognitive decline. [64] Elements of vascular dementia may be present in all other forms of dementia. [65]

Brain scans may show evidence of multiple strokes of different sizes in various locations. Risk factors include tobacco use, high blood pressure, atrial fibrillation, high cholesterol, diabetes, or other signs of vascular disease such as a previous heart attack or angina. [66]

Lewy body dementias

Lewy body dementias include dementia with Lewy bodies, and Parkinson's disease dementia. Parkinson's disease and dementia with Lewy bodies are synucleinopathies characterized by the presence of Lewy bodies in the brain. Parkinson's disease dementia, and dementia with Lewy bodies both present with similar signs and symptoms, and the only real difference between them is that Parkinson's disease precedes Parkinson's dementia typically by about a year. [67]

The prodromal symptoms of dementia with Lewy bodies (DLB) include mild cognitive impairment, and delirium onset. [68] The symptoms of DLB are more frequent, more severe, and earlier presenting than in the other subtypes. [69] Dementia with Lewy bodies has the primary symptoms of fluctuating cognition, alertness or attention; REM sleep behavior disorder (RBD); one or more of the main features of parkinsonism, not due to medication or stroke; and repeated visual hallucinations. [70] The visual hallucinations in DLB are generally vivid hallucinations of people or animals and they often occur when someone is about to fall asleep or wake up. Other prominent symptoms include problems with planning (executive dysfunction) and difficulty with visual-spatial function, [51] and disruption in autonomic bodily functions. [71] Abnormal sleep behaviors may begin before cognitive decline is observed and are a core feature of DLB. [70] RBD is diagnosed either by sleep study recording or, when sleep studies cannot be performed, by medical history and validated questionnaires. [70]

Frontotemporal dementias

Frontotemporal dementias (FTDs) are characterized by drastic personality changes, and language difficulties. In all types, early social withdrawal and lack of insight are major features but not memory problems. [72] The most common variant known as behavioral variant FTD (bv-FTD) presents major symptoms of changes in personality and behavior. The hallmark feature of bv-FTD is impulsive behavior, and this can be detected in pre-dementia states. [73] In bv-FTD, the person shows a change in personal hygiene, becomes rigid in their thinking, and rarely acknowledges problems; they are socially withdrawn, and often have a drastic increase in appetite. They may become socially inappropriate. For example, they may make inappropriate sexual comments, or may begin using pornography openly. One of the most common signs is apathy, or not caring about anything. Apathy, however, is a common symptom in many dementias. [51]

Other rare subtypes of FTD are three variants of primary progressive aphasia – language-led dementias that feature aphasia (language problems) as the main symptom. [12] One type is semantic dementia (or semantic PPA) with the main feature of the loss of the meaning of words. [74] Another type is called progressive nonfluent aphasia (or agrammatic PPA), mainly a difficulty in producing speech, not being able to find the right words, and also problems in coordinating the muscles needed for speech. Eventually the ability to talk at all may be lost. [74] The third type is logopenic progressive aphasia (discovered in 2004) and features impairment in the repetition of words or phrases, and impairment in retrieving words. [75]

A frontotemporal dementia (bvFTD) that overlaps with amyotrophic lateral sclerosis (ALS) is known as (FTD-ALS), and includes the symptoms of bvFTD (behavior, language and movement problems) and decline in motor functions of amyotrophic lateral sclerosis. [74] Two FTD-related disorders are progressive supranuclear palsy, and corticobasal degeneration, both of which are tauopathies. [74]

Mixed dementia

More than one type of dementia, known as mixed dementia, may exist together in at least 10% of dementia cases. The most common type of mixed dementia is Alzheimer's disease and vascular dementia, and the second most common is Alzheimer's and Lewy body dementia. Mixed dementia occurs more frequently in the elderly and seem to progress more rapidly. [14]

Diagnosis of mixed dementia can be difficult, as often only one type will predominate. This makes treatment uncommon, with many people missing out on potentially helpful treatments. Mixed dementia can mean that symptoms onset earlier, and worsen more quickly since more parts of the brain will be affected. [14]

Autoimmune dementia

Cognitive decline due to an autoimmune disease can be mistaken for that of a dementia subtype. The importance of correctly identifying an autoimmune dementia is critical in approved treatments. Being treated for dementia rules out immmunotherapy which could treat and reverse the disorder. Also to treat Alzheimer's with monoclonal antibodies would be contraindicated if there are unreported autoantibodies present. [76] [77]

Childhood dementias

There are many childhood dementias with a genetic cause. [78]

Early onset dementia

Around 7% of people over the age of 65 have dementia, with slightly higher rates (up to 10% of those over 65) in places with relatively high life expectancy. [79] Dementia can develop before the age of 65 when it is known as early onset dementia or young-onset dementia. [80]

Less than 1% of those with early-onset Alzheimer's dementia have genetic mutations that cause a much earlier onset, around the age of 45. [81]

Later onset dementia

A type of dementia has been classified as limbic-predominant age-related TDP-43 encephalopathy (LATE). It can only be diagnosed on autopsy when clusters of TDP-43 are found in the brain. It usually has a late onset typically affecting those over 80, and can also be found alongside Alzheimer's disease. [82]

Secondary dementias

Secondary dementias are those that develop from another condition, and include chronic traumatic encephalopathy, [83] Huntington's disease dementia, HIV-associated neurocognitive disorder, prion diseases, and alcohol use disorder.

Huntington's disease

Huntington's disease is a neurodegenerative disease caused by mutations in a single gene HTT, that encodes for huntingtin protein. Symptoms include cognitive impairment that usually declines further into dementia. Other symptoms include chorea (jerky movements), memory lapses, depression, stumbling and clumsiness, mood swings, and behavior changes such as impulsivity and irritability that can become more aggressive in later stages. [84]

HIV

HIV-associated dementia results as a late stage from HIV infection, and mostly affects younger people. [85] The essential features of HIV-associated dementia are disabling cognitive impairment accompanied by motor dysfunction, speech problems and behavioral change. [85] Cognitive impairment is characterised by mental slowness, trouble with memory and poor concentration. Motor symptoms include a loss of fine motor control leading to clumsiness, poor balance and tremors. Behavioral changes may include apathy, lethargy and diminished emotional responses and spontaneity. Histopathologically, it is identified by the infiltration of monocytes and macrophages into the central nervous system (CNS), gliosis, pallor of myelin sheaths, abnormalities of dendritic processes and neuronal loss. [86]

Prion diseases

Prion diseases typically cause dementia that worsens over weeks to months. Prion diseases are very rare and include include Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker syndrome, and fatal familial insomnia. Prions are misfolded proteins, that cause other proteins to misfold, and build up in the brain. [87]

Alcohol-related dementia, occurs as a result of alcohol-related brain damage due to alcoholism. Different factors can be involved in this development including thiamine deficiency and age vulnerability. A degree of brain damage is seen in more than 70% of cases of alcoholism. Brain regions affected are similar to those that are affected by aging, and also by Alzheimer's. Regions showing loss of volume include the frontal, temporal, and parietal lobes, as well as the cerebellum, thalamus, and hippocampus. This loss can be more notable, with greater cognitive impairments seen in those aged 65 years and over. [88]

Conditions with dementia-like symptoms

Autoimmune dementias of autoimmune disorder origin can mimic subtypes of dementia. They are potentially treatable if recognized and can have a good response to immunotherapy. [77]

Celiac disease does not seem to raise the risk of dementia in general but may increase the risk of vascular dementia. Both celiac disease or non-celiac gluten sensitivity might raise the risk of cognitive impairment which can be one of the early signs of subsequent dementia. A strict gluten-free diet started early may protect against vascular dementia associated with gluten-related disorders. [89]

Cases of easily reversible dementia include hypothyroidism, vitamin B12 deficiency, Lyme disease, and neurosyphilis. For Lyme disease and neurosyphilis, testing should be done if risk factors are present. Because risk factors are often difficult to determine, testing for neurosyphilis and Lyme disease, as well as other mentioned factors, may be undertaken as a matter of course where dementia is suspected. [51] :31–32

Cognitive impairment also occurs in the Parkinson-plus syndromes of progressive supranuclear palsy and corticobasal degeneration (and the same underlying pathology may cause the clinical syndromes of frontotemporal lobar degeneration). Although the acute porphyrias may cause episodes of confusion and psychiatric disturbance, dementia is a rare feature of these rare diseases.[ citation needed ]

Hereditary disorders that can also cause dementia include: some metabolic disorders such as lysosomal storage disorders, leukodystrophies, and spinocerebellar ataxias.

Diagnosis

Symptoms are similar across dementia types and it is difficult to diagnose by symptoms alone. A medical history will be taken and blood tests may be routinely carried out to rule out possible treatable causes such as vitamin deficiencies and hormone imbalances. A number of cognitive tests are available to test degrees of cognitive impairment. Diagnosis may be further aided by brain scans. In those who are getting older, general screening for cognitive impairment using cognitive tests for early diagnosis of dementia has not been shown to improve outcomes. [16] [90]

Normally, symptoms must be present for at least six months to support a diagnosis. [91] Cognitive dysfunction of shorter duration is called delirium . Delirium can be easily confused with dementia due to similar symptoms. Delirium is characterized by a sudden onset, fluctuating course, a short duration (often lasting from hours to weeks), and is primarily related to a somatic (or medical) disturbance. In comparison, dementia has typically a long, slow onset (except in the cases of a stroke or trauma), slow decline of mental functioning, as well as a longer trajectory (from months to years). [92]

Some mental illnesses, including depression and psychosis, may produce symptoms that must be differentiated from both delirium and dementia. [93] These are differently diagnosed as pseudodementias, and any dementia evaluation needs to include a depression screening such as the Neuropsychiatric Inventory or the Geriatric Depression Scale. [94] [51] Physicians used to think that people with memory complaints had depression and not dementia (as they thought that those with dementia are generally unaware of their memory problems). However, researchers have since realized that many older people with memory complaints in fact have mild cognitive impairment, the earliest stage of dementia. Depression should always remain high on the list of possibilities, however, for an elderly person with memory trouble. Changes in thinking, hearing and vision are associated with normal ageing and can cause problems when diagnosing dementia due to the similarities. [95] Given the challenging nature of predicting the onset of dementia and making a dementia diagnosis clinical decision making aids underpinned by machine learning and artificial intelligence have the potential to enhance clinical practice. [96]

Screening

Sensitivity and specificity of common tests for dementia
Test Sensitivity Specificity Reference
MMSE71–92%56–96% [97]
3MS83–93%85–90% [98]
AMTS73–100%71–100% [98]

Various brief cognitive tests (5–15 minutes) have reasonable reliability to screen for dementia, but may be affected by factors such as age, education and ethnicity. [99] Age and education have a significant influence on the diagnosis of dementia. For example, Individuals with lower education are more likely to be diagnosed with dementia than their educated counterparts. [100] The mini mental state examination (MMSE) is the best studied and most commonly used screening test. [33] The MMSE is a useful tool for helping to diagnose dementia if the results are interpreted along with an assessment of a person's personality, their ability to perform activities of daily living, and their behavior. [4] Other cognitive tests include the abbreviated mental test score (AMTS), the, "modified mini–mental state examination" (3MS), [101] the Cognitive Abilities Screening Instrument (CASI), [102] the Trail-making test, [103] and the clock drawing test. [36] The MoCA (Montreal Cognitive Assessment) is a reliable screening test and is available online for free in 35 different languages. [51] The MoCA has also been shown somewhat better at detecting mild cognitive impairment than the MMSE. [104] [40] People with hearing loss, which commonly occurs alongside dementia, score worse in the MoCA test, which could lead to a false diagnosis of dementia. Researchers have developed an adapted version of the MoCA test, which is accurate and reliable and avoids the need for people to listen and respond to questions. [105] [106] The AD-8 – a screening questionnaire used to assess changes in function related to cognitive decline – is potentially useful, but is not diagnostic, is variable, and has risk of bias. [107] An integrated cognitive assessment (CognICA) is a five-minute test that is highly sensitive to the early stages of dementia, and uses an application deliverable to an iPad. [108] [109] Previously in use in the UK, in 2021 CognICA was given FDA approval for its commercial use as a medical device. [109]

Another approach to screening for dementia is to ask an informant (relative or other supporter) to fill out a questionnaire about the person's everyday cognitive functioning. Informant questionnaires provide complementary information to brief cognitive tests. Probably the best known questionnaire of this sort is the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). [110] Evidence is insufficient to determine how accurate the IQCODE is for diagnosing or predicting dementia. [111] The Alzheimer's Disease Caregiver Questionnaire is another tool. It is about 90% accurate for Alzheimer's when by a caregiver. [51] The General Practitioner Assessment Of Cognition combines both a patient assessment and an informant interview. It was specifically designed for use in the primary care setting.

Clinical neuropsychologists provide diagnostic consultation following administration of a full battery of cognitive testing, often lasting several hours, to determine functional patterns of decline associated with varying types of dementia. Tests of memory, executive function, processing speed, attention and language skills are relevant, as well as tests of emotional and psychological adjustment. These tests assist with ruling out other etiologies and determining relative cognitive decline over time or from estimates of prior cognitive abilities. [112]

Imaging

A CT scan or MRI scan is commonly performed to possibly find either normal pressure hydrocephalus, a potentially reversible cause of dementia, or connected tumor. The scans can also yield information relevant to other types of dementia, such as a stroke that would indicate a vascular type of dementia. [113]

The functional neuroimaging modalities of SPECT and PET are more useful in assessing long-standing cognitive dysfunction, since they have shown similar ability to diagnose dementia as a clinical exam and cognitive testing. [114] The ability of SPECT to differentiate vascular dementia from Alzheimer's disease, appears superior to differentiation by clinical exam. [115]

Prevention

Risk factors

In a global report of 2017, nine risk factors for dementia were recognized. These were, lower levels of education, high blood pressure, hearing impairment, smoking, obesity, depression, physical inactivity, diabetes, and low social contact. [116] In 2020 the reviewed report added three more – excessive alcohol use, traumatic brain injury and air pollution. [116] The 2024 report added two more of visual impairment, and high cholesterol. [3] [117]

Many of the now fourteen risk factors for dementia, are potentially modifiable. [3] [118] [119] Their management can reduce the risk of dementia in late midlife or older age and give a positive outcome. [120] The decreased risk achieved by adopting a healthy lifestyle is seen even in those with a high genetic risk. [121]

In addition to the above risk factors, other psychological features, including certain personality traits (high neuroticism, and low conscientiousness), low purpose in life, and feeling lonely, are also risk factors for dementia. [122] [123] [74] For example, based on the English Longitudinal Study of Ageing (ELSA), research found that loneliness (but not social isolation) in older people can increase the risk of dementia by one-third. Living alone can double the risk of dementia. However, having two or three closer relationships might reduce the risk by three-fifths. [124] [125]

The two most modifiable risk factors for dementia are physical inactivity and lack of cognitive stimulation. [126] Physical activity, in particular aerobic exercise, is associated with a reduction in age-related brain tissue loss, and neurotoxic factors thereby preserving brain volume and neuronal integrity. Cognitive activity strengthens neural plasticity and together they help to support cognitive reserve. The neglect of these risk factors diminishes this reserve. [126]

Sensory impairments of vision and hearing are modifiable risk factors for dementia. [127] [128] These impairments may precede the cognitive symptoms of Alzheimer's disease for example, by many years. [129] Hearing loss may lead to social isolation which negatively affects cognition. [130] Social isolation is also identified as a modifiable risk factor. [129] Age-related hearing loss in midlife is linked to cognitive impairment in late life, and is seen as a risk factor for the development of Alzheimer's disease and dementia. Such hearing loss may be caused by a central auditory processing disorder that makes the understanding of speech against background noise difficult. Age-related hearing loss is characterised by slowed central processing of auditory information. [129] [131] Worldwide, mid-life hearing loss may account for around 9% of dementia cases. [132] Hearing loss is not a recognised risk factor for vascular dementia. [128]

Frailty may increase the risk of cognitive decline, and dementia, and the inverse also holds of cognitive impairment increasing the risk of frailty. Prevention of frailty may help to prevent cognitive decline. [129]

There are no medications that can prevent cognitive decline and dementia. [133] However blood pressure lowering medications might decrease the risk of dementia or cognitive problems by around 0.5%. [134]

Economic disadvantage has been shown to have a strong link to higher dementia prevalence, [135] which cannot yet be fully explained by other risk factors.

An economic model has proposed that population-level interventions in England that target dementia risk factors such as high blood pressure, smoking and obesity, could save money and give people extra years in good health. For example, reduced salt in food could give 39,433 quality-adjusted life-years and save £2.4 billion. [136]

Dental health

Limited evidence links poor oral health to cognitive decline. However, failure to perform tooth brushing and gingival inflammation can be used as dementia risk predictors. [137]

Oral bacteria

There is some evidence that oral bacteria in people with gum disease may be a link to declines in cognitive health. [138] The proposed mechanism is still being studied, but research has linked specific types of bacteria in the mouth to those found in some people's brain who have Alzheimer's disease. There is also some evidence that people with a high level of tooth plaque are also at a greater risk of cognitive decline. [139] Poor oral hygiene can have an adverse effect on speech and nutrition, causing general and cognitive health decline.[ citation needed ]

Oral viruses

Herpes simplex virus (HSV) has been found in more than 70% of those aged over 50. HSV persists in the peripheral nervous system and can be triggered by stress, illness or fatigue. [140] High proportions of viral-associated proteins in amyloid plaques or neurofibrillary tangles (NFTs) confirm the involvement of HSV-1 in Alzheimer's disease pathology. NFTs are known as the primary marker of Alzheimer's disease. HSV-1 produces the main components of NFTs. [141] A Swedish cohort study from 2024 suggests that persons infected with HSV have twice the risk of developing dementia compared to non-infected participants. [142]

Diet

A modifiable risk factor for dementia is diet. Thiamine deficiency for example, a low level of thiamine (vitamin B1), an essential micronutrient is an identified risk factor for dementia. [143] [144]

The Mediterranean and DASH diets are both associated with less cognitive decline. A different approach has been to incorporate elements of both of these diets into one known as the MIND diet. [144] These diets are generally low in saturated fats while providing a good source of carbohydrates, mainly those that help stabilize blood sugar and insulin levels. [145] Raised blood sugar levels over a long time, can damage nerves and cause memory problems if they are not managed. [146] Nutritional factors associated with the proposed diets for reducing dementia risk include unsaturated fatty acids, vitamin E, vitamin C, flavonoids, vitamin B, and vitamin D. [147] [148] A study conducted at the University of Exeter in the United Kingdom seems to have confirmed these findings with fruits, vegetables, whole grains, and healthy fats creating an optimum diet that can help reduce the risk of dementia by roughly 25%. [149]

The MIND diet may be more protective but further studies are needed. The Mediterranean diet seems to be more protective against Alzheimer's than DASH but there are no consistent findings against dementia in general. The role of olive oil needs further study as it may be one of the most important components in reducing the risk of cognitive decline and dementia. [144] [150]

In those with celiac disease or non-celiac gluten sensitivity, a strict gluten-free diet may relieve the symptoms given a mild cognitive impairment. [89] [151] Once dementia is advanced no evidence suggests that a gluten-free diet is useful. [89]

Omega-3 fatty acid supplements do not appear to benefit or harm people with mild to moderate symptoms, but there is good evidence that they help in treating the common symptom of depression, and a potential risk factor for dementia. [152] [3]

Management

There are several non-pharmacological, and limited pharmacological options for treating dementia, and no available options to delay the onset or stop the progression. Some types of medication are used to address the symptoms in different subtypes but the benefit is small. [153]

More than half of people with dementia may experience psychological or behavioral symptoms including agitation, sleep problems, aggression, and/or psychosis. Treatment for these symptoms is aimed at reducing the person's distress and keeping the person safe. Treatments other than medication appear to be better for agitation and aggression. [154] Cognitive and behavioral interventions may be appropriate. Some evidence suggests that education and support for the person with dementia, as well as caregivers and family members, improves outcomes. [155] Exercise programs are beneficial with respect to activities of daily living. [156] As with all brain disorders, some people with dementia could potentially be a danger to themselves or others. Such behavioral symptoms might result in the person being involuntarily admitted to a mental health ward for assessment, care and treatment. However, this is a last resort, and potential alternatives could be considered by family or friends of people with dementia. [157] [158]

Palliative care interventions may lead to improvements in the quality of life, management of symptoms, and comfort in dying, but it is not yet known how it can be best used to support people dying with advanced dementia and their families. [159]

The effect of therapies can be evaluated for example by assessing agitation using the Cohen-Mansfield Agitation Inventory (CMAI); by assessing mood and engagement with the Menorah Park Engagement Scale (MPES); [160] and the Observed Emotion Rating Scale (OERS) [161] or by assessing indicators for depression using the Cornell Scale for Depression in Dementia (CSDD) [162] or a simplified version thereof. [163]

Often overlooked in treating and managing dementia is the role of the caregiver and what is known about how they can support multiple interventions. Caregivers of people with dementia in nursing homes do not have sufficient tools or clinical guidance for behavioral and psychological symptoms of dementia (BPSD) along with medication use. [164] Simple measures like talking to people about their interests can improve the quality of life for care home residents living with dementia. A programme showed that such simple measures reduced residents' agitation and depression. They also needed fewer GP visits and hospital admissions, which also meant that the programme was cost-saving. [165] [166]

Psychological and psychosocial therapies

Psychological therapies for dementia include some limited evidence for reminiscence therapy (namely, some positive effects in the areas of quality of life, cognition, communication and mood – the first three particularly in care home settings), [167] some benefit for cognitive reframing for caretakers, [168] unclear evidence for validation therapy [169] and tentative evidence for mental exercises, such as cognitive stimulation programs for people with mild to moderate dementia. [170] Offering personally tailored activities may help reduce challenging behavior and may improve quality of life. [171] It is not clear if personally tailored activities have an impact on affect or improve for the quality of life for the caregiver. [171]

Adult daycare centers as well as special care units in nursing homes often provide specialized care for dementia patients. Daycare centers offer supervision, recreation, meals, and limited health care to participants, as well as providing respite for caregivers. In addition, home care can provide one-to-one support and care in the home allowing for more individualized attention that is needed as the disorder progresses. Psychiatric nurses can make a distinctive contribution to people's mental health. [172]

Dementia impairs normal communication and agitated behavior is often used to indicate pain, illness, or overstimulation. [173] The strongest evidence for non-pharmacological therapies for the management of changed behaviors in dementia is for using such approaches. [174] Low quality evidence suggests that regular (at least five sessions of) music therapy may help institutionalized residents. It may reduce depressive symptoms and improve overall behaviors. It may also supply a beneficial effect on emotional well-being and quality of life, as well as reduce anxiety. [175] In 2003, The Alzheimer's Society established 'Singing for the Brain' (SftB) a project based on pilot studies which suggested that the activity encouraged participation and facilitated the learning of new songs. The sessions combine aspects of reminiscence therapy and music. [176] Musical and interpersonal connectedness can underscore the value of the person and improve quality of life. [177]

Some London hospitals found that using color, designs, pictures and lights helped people with dementia adjust to being at the hospital. These adjustments to the layout of the dementia wings at these hospitals helped patients by preventing confusion. [178]

Life story work as part of reminiscence therapy, and video biographies have been found to address the needs of clients and their caregivers in various ways, offering the client the opportunity to leave a legacy and enhance their personhood and also benefitting youth who participate in such work. Such interventions can be more beneficial when undertaken at a relatively early stage of dementia. They may also be problematic in those who have difficulties in processing past experiences [177]

Animal-assisted therapy particularly with the use of dogs, has been found to be helpful. [177]

Occupational therapy also addresses psychological and psychosocial needs of patients with dementia through improving daily occupational performance and caregivers' competence. [179] When compensatory intervention strategies are added to their daily routine, the level of performance is enhanced and reduces the burden commonly placed on their caregivers. [179] Occupational therapists can also work with other disciplines to create a client centered intervention. [180] To manage cognitive disability, and coping with behavioral and psychological symptoms of dementia, combined occupational and behavioral therapies can support patients with dementia even further. [180]

Cognitive training and rehabilitation

There is no strong evidence to suggest that cognitive training is beneficial for people with Parkinson's disease, dementia, or mild cognitive impairment. [181] However, a 2023 review found that cognitive rehabilitation may be effective in helping individuals with mild to moderate dementia to manage their daily activities. [182]

Personally tailored activities

Offering personally tailored activity sessions to people with dementia in long-term care homes may slightly reduce challenging behavior. [183]

Medications

Donepezil Donepezil skeletal.svg
Donepezil

There are some medications used in the treatment of symptoms of the different dementias. Acetylcholinesterase inhibitors, such as donepezil, may be useful for Alzheimer's disease. [184] Moderate-quality evidence shows that donepezil provides small improvements in cognition, daily functioning, and global clinical state in Alzheimer's disease, with higher doses slightly increasing benefit but also adverse events. [185] No difference has been shown between the agents in this family. [186] In a minority of people side effects include a slow heart rate and fainting. [187] Rivastigmine is recommended for treating symptoms in Parkinson's disease dementia. [6]

Medications that have anticholinergic effects increase all-cause mortality in people with dementia, although the effect of these medications on cognitive function remains uncertain, according to a systematic review published in 2021. [188]

Before prescribing antipsychotic medication in the elderly, an assessment for an underlying cause of the behavior is needed. [189] Severe and life-threatening reactions occur in almost half of people with DLB, [71] [190] and can be fatal after a single dose. [191] People with Lewy body dementias who take neuroleptics are at risk for neuroleptic malignant syndrome, a life-threatening illness. [192] Extreme caution is required in the use of antipsychotic medication in people with DLB because of their sensitivity to these agents. [70] Antipsychotic drugs are used to treat dementia only if non-drug therapies have not worked, and the person's actions threaten themselves or others. [193] [194] [195] [196] Aggressive behavior changes are sometimes the result of other solvable problems, that could make treatment with antipsychotics unnecessary. [193] Because people with dementia can be aggressive, resistant to their treatment, and otherwise disruptive, sometimes antipsychotic drugs are considered as a therapy in response. [193] These drugs have risky adverse effects, including increasing the person's chance of stroke and death. [193] Given these adverse events and small benefit antipsychotics are avoided whenever possible. [174] Generally, stopping antipsychotics for people with dementia does not cause problems, even in those who have been on them a long time. [197]

Memantine provides a small but consistent benefit for moderate-to-severe Alzheimer's disease, regardless of cholinesterase inhibitor use, but shows no clear benefit and may increase adverse events in mild Alzheimer's, with limited evidence for other dementias. [198] Due to their differing mechanisms of action memantine and acetylcholinesterase inhibitors can be used in combination however the benefit is slight. [199] [200]

An extract of Ginkgo biloba known as EGb 761 has been widely used for treating mild to moderate dementia and other neuropsychiatric disorders. [201] Its use is approved throughout Europe. [202] The World Federation of Biological Psychiatry guidelines lists EGb 761 with the same weight of evidence (level B) given to acetylcholinesterase inhibitors, and memantine. EGb 761 is the only one that showed improvement of symptoms in both AD and vascular dementia. EGb 761 is seen as being able to play an important role either on its own or as an add-on particularly when other therapies prove ineffective. [201] EGb 761 is seen to be neuroprotective; it is a free radical scavenger, improves mitochondrial function, and modulates serotonin and dopamine levels. Many studies of its use in mild to moderate dementia have shown it to significantly improve cognitive function, activities of daily living, neuropsychiatric symptoms, and quality of life. [201] [203] However, its use has not been shown to prevent the progression of dementia. [201]

While depression is frequently associated with dementia, the use of antidepressants such as selective serotonin reuptake inhibitors (SSRIs) do not appear to affect outcomes. [204] [205] However, the SSRIs sertraline and citalopram have been demonstrated to reduce symptoms of agitation, compared to placebo. [206]

No solid evidence indicates that folate or vitamin B12 improves outcomes in those with cognitive problems. [207] A Cochrane review found no evidence that statins prevent dementia. [208] Medications for other health conditions may need to be managed differently for a person who has a dementia diagnosis. It is unclear whether blood pressure medication and dementia are linked. People may experience an increase in cardiovascular-related events if these medications are withdrawn. [209]

The Medication Appropriateness Tool for Comorbid Health Conditions in Dementia (MATCH-D) criteria can help identify ways that a diagnosis of dementia changes medication management for other health conditions. [210] These criteria were developed because people with dementia live with an average of five other chronic diseases, which are often managed with medications. The systematic review that informed the criteria were published subsequently in 2018 and updated in 2022. [211]

Palliative care

In late stage dementia, palliative care, the total care by a team of healthcare providers can be helpful to both the individual and the caregiver. [43] It aims to improve quality of life. [212] A palliative care approach can support people affected by dementia at any stage of the condition. It can help people with dementia and their caregivers to understand what to expect, deal with loss of physical and mental abilities, support the person's wishes and goals including surrogate decision making, and discuss wishes for or against CPR and life support. [213]

Because there is uncertainty around how and when people with dementia decline, and because most people prefer to allow the person with dementia to make their own decisions, palliative care involvement before the late stages of dementia is recommended. [214] In the early stages of dementia, palliative care can involve advocacy around establishing goals of care in the future, reassurance of continued support, planning for future scenarios of care and establishing long-term relationships with care providers. [215] In later stages, a palliative approach to dementia care may have specific benefit to goals of care and end-of-life conversations, symptom management, prescribing practices and emergency department visits. [216] However, more research is needed to know how palliative care can be best used to support people dying with advanced dementia and their families. [217]

Towards the end of life, people with dementia frequently present to the emergency department with unmet palliative care needs. [218] Community palliative care is associated with the reduced likelihood of attending the emergency department among people with dementia nearing the end of life. [219] Palliative care for people with dementia living at home may help improve end-of-life care outcomes such as neuropsychiatric symptoms. [220]

People with advanced dementia may not readily receive specialist palliative care input. [221] Reasons for this are varied but may include lack of agreement of when to refer people with dementia, [222] and a lack of coordination across care settings, communication challenges, limited training opportunities for healthcare staff and because dementia is considered to be a life-limiting condition. [221] In fact, people with dementia and their carers and members of the public often don't know that dementia is not a normal part of aging and that it is a terminal condition. [19] [223]

Further research is needed to determine the appropriate palliative care interventions and how they can be implemented to help people with dementia. [159] [220]

Person-centered care

Person-centered care (different from patient participation), takes into account the individual's needs, preferences, experiences, and values. It is built on getting to know the person with the condition through a personal relationship. [224] This is especially important as the approach aims to maintain the dignity of people with dementia and sense of identity throughout the course of their illness. [225]

Person-centered care interventions could not only reduce agitation, neuropsychiatric symptoms, and depression but also help improve the quality of life for people with dementia. [226] Moreover, the potential benefits of a person-centered care approach for dementia care workers have been reported, indicating its effectiveness in reducing stress, burnout, and job dissatisfaction. [224] [227] Person-centered outcome measures (PCOMs) are standardized, validated questionnaires that measure people's opinions of their own health and well-being. They emphasize person-centered care by focusing on the symptoms and concerns that are most important to people and their families. [228] [229] PCOMs may be self-reported (when the person with dementia completes the questionnaire) or proxy-reported (when the questionnaire is completed by someone who knows them well). Proxy-reported PCOMs are used in more advanced stages of dementia when the person is no longer able to self report. [228] Used in routine care, PCOMs support systematic assessment and monitoring of an individual's health and wellbeing, enable shared decision-making, enable changes in care provision (such as improved communication or referral to other services), improve outcomes (such as improved symptom management) and enable evaluation of care provision. [228] The use of PCOMs have the potential to serve as a scalable and sustainable way to support integrated palliative care for older people including those living with dementia. [229]

PCOMs can be single-domain or multi-domain tools, focussing on individual symptoms or multiple symptoms, depending on the scope of assessment. [230] Single-domain PCOMs focus on one specific area of care. For example, the Pain Assessment in Advanced Dementia scale is used to assess pain in individuals living with advanced dementia. [231] Multi-domain PCOMs assess multiple domains, including, for example, symptom burden, function, psychological, and spiritual concerns. The Integrated Palliative Care Outcome Scale for Dementia (IPOS-Dem) is an example of a comprehensive palliative dementia PCOM, used to measure symptoms and concerns for people with dementia and their family. [232]

Sleep disturbances

Over 40% of people with dementia report sleep problems. [233] Approaches to treating these sleep problems include medications and non-pharmacological approaches. [233] The use of medications to alleviate sleep disturbances has not been well researched, even for medications that are commonly prescribed. [234] In 2012 the American Geriatrics Society recommended that benzodiazepines such as diazepam, and non-benzodiazepine sleeping pills, be avoided for people with dementia due to the risks of increased cognitive impairment and falls. [235] Benzodiazepines are also known to promote delirium. [236] Additionally, little evidence supports the effectiveness of benzodiazepines in this population. [234] [237] No clear evidence shows that melatonin or ramelteon improves sleep for people with dementia due to Alzheimer's, [234] but it is used to treat REM sleep behavior disorder in dementia with Lewy bodies. [71] Limited evidence suggests that a low dose of trazodone may improve sleep, however more research is needed. [234]

Non-pharmacological approaches have been suggested but there is no strong evidence or firm conclusions on the effectiveness of different types of interventions, especially for those who are living in an institutionalized setting such as a nursing home or long-term care home. [233]

Pain

As people age, they experience more health problems, and most health problems associated with aging carry a substantial burden of pain; therefore, between 25% and 50% of older adults experience persistent pain. Seniors with dementia experience the same prevalence of conditions likely to cause pain as seniors without dementia. [238] Pain is often overlooked in older adults and, when screened for, is often poorly assessed, especially among those with dementia, since they become incapable of informing others of their pain. [238] [239] Beyond the issue of humane care, unrelieved pain has functional implications. Persistent pain can lead to decreased ambulation, depressed mood, sleep disturbances, impaired appetite, and exacerbation of cognitive impairment [239] and pain-related interference with activity is a factor contributing to falls in the elderly. [238] [240]

Although persistent pain in people with dementia is difficult to communicate, diagnose, and treat, failure to address persistent pain has profound functional, psychosocial and quality of life implications for this vulnerable population. Health professionals often lack the skills and usually lack the time needed to recognize, accurately assess and adequately monitor pain in people with dementia. [238] [241] Family members and friends can make a valuable contribution to the care of a person with dementia by learning to recognize and assess their pain. Educational resources and observational assessment tools are available. [238] [242] [243]

Eating difficulties

Persons with dementia may have difficulty eating. Whenever it is available as an option, the recommended response to eating problems is having a caretaker assist them. [193] For people who do not have dementia, a secondary option when they cannot swallow effectively would be to consider gastrostomy feeding tube placement as a way to give nutrition. However, for people with dementia, assistance with oral feeding is at least as good as tube feeding in bringing comfort and maintaining functional status while lowering risk of aspiration pneumonia and death [193] [244] It can be tried if the reasons for the person's problems with eating, drinking or swallowing are treatable and it's expected that they will be able to start eating and drinking normally afterwards. [245] Tube-feeding is associated with agitation, increased use of physical and chemical restraints and worsening pressure ulcers. Tube feedings may cause fluid overload, diarrhea, abdominal pain, local complications, less human interaction and may increase the risk of aspiration. [246] [247]

Benefits in those with advanced dementia has not been shown. [248] The risks of using tube feeding include agitation, rejection by the person (pulling out the tube, or otherwise physical or chemical immobilization to prevent them from doing this), or developing pressure ulcers. [193] The procedure is directly related to a 1% fatality rate [249] with a 3% major complication rate. [250] The percentage of people at end of life with dementia using feeding tubes in the US has dropped from 12% in 2000 to 6% as of 2014. [251] [252]

The immediate and long-term effects of modifying the thickness of fluids for swallowing difficulties in people with dementia are not well known. [253] While thickening fluids may have an immediate positive effect on swallowing and improving oral intake, the long-term impact on the health of the person with dementia should also be considered. [253]

Exercise

Exercise programs may improve the ability of people with dementia to perform daily activities, but the best type of exercise is still unclear. [254] Getting more exercise can slow the development of cognitive problems such as dementia, proving to reduce the risk of Alzheimer's disease by about 50%. A balance of strength exercise, to help muscles pump blood to the brain, and balance exercises are recommended for aging people. A suggested amount of about 2+12 hours per week can reduce risks of cognitive decay as well as other health risks like falling. [255]

Assistive technology and digital health

There is a lack of high-quality scientific evidence to determine whether assistive technology effectively supports people with dementia to manage memory issues. [256] Some of the specific things that are used today that helps with dementia today are: clocks, communication aids, electrical appliances the use monitoring, GPS location/ tracking devices, home care robots, in-home cameras, and medication management are just to name a few. [257] As the technology advances, virtual reality is also being explored as a powerful technology to elicit memories and to improve wellbeing. [258]

Technology has the potential to be a valuable intervention for alleviating loneliness and promoting social connections. [259] It could facilitate activities of daily living, and provide ways to connect people that are geographically distant. [260]

Other types of developed technologies to aid services include telehealth or telemedicine services, using digital communication for delivery of health-related services and information through phone calls, mobile apps, and video conferencing. [261]

Telemedicine has given results for cognitive assessment and diagnosis that are similar to in-person visits, and it has also helped improve outcomes after rehabilitation. Telemedicine is often well received by people affected by dementia who can rely on the support of staff and family to navigate the technology. While it has potential to widen access to services, those with sensory impairment may be excluded. [261]

Digital health interventions can play a role in supporting family caregivers of people with dementia, by offering a source of support from connective platforms, with 24/7 accessibility, as well as opportunity for remote monitoring. However, challenges such as the digital divide, privacy concerns and the need for greater personalisation for individual users are recognised issues. [261]

Remotely delivered information for caregivers

Remotely delivered interventions including support, training and information may reduce the burden for the informal caregiver and improve their depressive symptoms. [262] There is no certain evidence that they improve health-related quality of life. [262]

In several localities in Japan, digital surveillance may be made available to family members, if a person with dementia is prone to wandering and going missing. [263]

Alternative medicine

Scientific evidence of the therapeutic values of aromatherapy and massage is unclear and limited. There is no convincing evidence about their effectiveness but no general conclusions can be drawn about the benefits or harms of these alternative treatments. [264] [265] It is not clear if cannabinoids have any harmful or beneficial effects on dementia. [266]

Epidemiology

Dementia death rates Dementia death rates, World, 2021 (cropped).svg
Dementia death rates
Disability-adjusted life year for Alzheimer and other dementias per 100,000 inhabitants in 2004
.mw-parser-output .col-begin{border-collapse:collapse;padding:0;color:inherit;width:100%;border:0;margin:0}.mw-parser-output .col-begin-small{font-size:90%}.mw-parser-output .col-break{vertical-align:top;text-align:left}.mw-parser-output .col-break-2{width:50%}.mw-parser-output .col-break-3{width:33.3%}.mw-parser-output .col-break-4{width:25%}.mw-parser-output .col-break-5{width:20%}@media(max-width:720px){.mw-parser-output .col-begin,.mw-parser-output .col-begin>tbody,.mw-parser-output .col-begin>tbody>tr,.mw-parser-output .col-begin>tbody>tr>td{display:block!important;width:100%!important}.mw-parser-output .col-break{padding-left:0!important}}
.mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{}
<100
100-120
120-140
140-160
160-180
180-200
200-220
220-240
240-260
260-280
280-300
>300 Alzheimer and other dementias world map - DALY - WHO2004.svg
Disability-adjusted life year for Alzheimer and other dementias per 100,000 inhabitants in 2004

The number of cases of dementia worldwide in 2021 was estimated at 57 million, with close to 10 million new cases each year. [1] It is (as of 2026) the seventh leading cause of death with some 1.8 million lost lives in 2021. [1] [267] By 2050, the number of people living with dementia around the world is estimated to be over 150 million. [268] Globally, the fastest increase in serious health-related suffering by 2060 is expected to occur among people with dementia. [269]

Around 7% of people over the age of 65 have dementia, with slightly higher rates, up to 10%, in places with relatively high life expectancy. [79] An estimated 58% of people with dementia are living in low and middle income countries. [270]

The prevalence of dementia differs in different world regions, ranging from 4.7% in Central Europe to 8.7% in North Africa/Middle East; the prevalence in other regions is estimated to be between 5.6 and 7.6%. [270] The number of people living with dementia is estimated to double every 20 years. [270]

Estimates show that in 2024 there were 982,000 people living with dementia in the UK and this is expected to rise to 1.4 million people by 2040. [271]

The annual incidence of dementia diagnosis is nearly 10 million worldwide. [159] Almost half of new dementia cases occur in Asia, followed by Europe (25%), the Americas (18%) and Africa (8%). The incidence of dementia increases exponentially with age, doubling with every 6.3-year increase in age. [270] Dementia affects 5% of the population older than 65 and 20–40% of those older than 85. [272] Rates are slightly higher in women than men at ages 65 and greater. [272] The disease trajectory is varied and the median time from diagnosis to death depends strongly on age at diagnosis, from 6.7 years for people diagnosed aged 60–69 to 1.9 years for people diagnosed at 90 or older. [159]

In 2019, there were 1.62 million dementia-related deaths worldwide. This is expected to increase to 4.91 million by 2050. [7]

In 2022 and 2023, dementia was the leading cause of death in England and Wales. [17]

Deaths from dementia in the U.S. have tripled in the past 21 years, rising from around 150,000 in 1999 to over 450,000 in 2020, and the likelihood of dying from dementia increased across all demographic groups. [273]

The genetic and environmental risk factors for dementia disorders vary by ethnicity. [274] [275] For instance, Alzheimer's disease among Hispanic/Latino and African American subjects exhibit lower risks associated with gene changes in the apolipoprotein E gene than do non-Hispanic white subjects. [276]

In the United States in 2017, over 37% of dementia cases were associated with cardiometabolic conditions, though the risk varies across regions. The eight key contributors were diabetes, heart failure, atrial fibrillation, coronary artery disease, heart attacks, strokes, hypertension and high cholesterol. Among these, stroke was the most significant factor, doubling the risk of developing dementia (2.2 times higher), followed closely by heart failure (2.1 times) and hypertension (78% increased risk). In contrast, high cholesterol had the weakest correlation, associated with a 27% increased risk. However, there were also geographic disparities, and individuals living in the U.S. South faced a higher likelihood of dementia related to cardiovascular conditions and diabetes. [277] [278]

Inequities and inequalities

A growing body of scientific evidence suggests that inequalities and inequities in dementia exist. Inequalities and inequities are observed in the risk of developing dementia, ability to take part in prevention efforts, access to high-quality dementia care from diagnosis until the end of life, including bereavement support. [279]

Post-diagnostic care is often variable and difficult to navigate, [280] [281] [282] with a disparity in care between dementia and other life-limiting conditions. [283] [284] [285] Furthermore, substantially less dementia research funding and financial support for the care of people with dementia compared to other life-limiting conditions also exists. [279]

Differences in access to high-quality care among dementia subtypes are also noted. People with rare types of dementia compared to those with Alzheimer's Disease, and those with other physical conditions are less likely to experience high-quality care. [286]

People with dementia are often physically or chemically restrained to a greater degree than necessary, raising issues of human rights. [1] Social stigma is commonly perceived by those with the condition, and also by their caregivers. [90]

Socioeconomic status and deprivation

While aging is the largest risk factor for developing dementia, other factors at early (e.g., receiving less education), middle (e.g., physical inactivity) and later stages (e.g., air pollution) are often linked to increased risk. [3] For instance, long-term air pollution is associated with higher dementia risk, since risk increases with greater exposure to fine particulate matter (PM2.5), nitrogen dioxide, and black carbon. [119] [287]

There are significant advantages associated with having a timely dementia diagnosis (i.e., receiving the diagnosis at the milder stages of the condition). However, access to dementia diagnosis can be inequitable. Compared to individuals with high socioeconomic status, those with low socioeconomic status can have more than three-times higher risk of early-onset dementia. Additionally, individuals of low socioeconomic status with unhealthy lifestyles, can have 440% greater risk of developing early-onset dementia compared with individuals of high socioeconomic status with healthy lifestyles. [3] Measures to improve social determinants of health are warranted, as healthy lifestyle promotion alone might not substantially reduce the socioeconomic inequity in early-onset dementia and late-onset dementia risk.

People with dementia residing in rural areas often experience challenges in receiving a timely diagnosis and accessing health and social care compared to people living in urban areas. [288]

Among older people diagnosed with dementia, those from most deprived areas can be more likely to experience hospitalisations, emergency department visits, potentially inappropriate medication prescriptions, and higher 1-year mortality. [289] People living in the most deprived areas are more likely to experience multiple hospitalisations in the last three months of life and emergency department visits in the last year of life. [290] [291] In high-income countries, low socioeconomic position is a risk factor for dying in hospital as well as other indicators of potentially poor-quality end-of-life care. [292]

Race and ethnicity

Significant differences in dementia incidence and risk exist based on race and ethnicity. The mechanisms responsible for these differences are not yet understood. [293] [294] People who are Black in the US are at risk of receiving more futile and invasive treatment towards the end of life. [295] Emerging evidence from other countries also suggest that minority groups from different cultures, ethnicities may experience sub-optimal care from diagnosis to the end-of-life. [296] [290] [297] [298]

Gender

Globally, women are much more impacted by dementia than men. Two in three people with dementia are women. Yet, medical data from women are lacking compared to men. Women are more likely to care for another person with dementia (in the workforce and informally). The proportion of women caregivers in low and middle income countries is higher. [299] [300] Gender disparities exist towards the end-of-life in palliative caregiving and end-of-life care experiences. [301]

History

Until the end of the 19th century, dementia was a much broader clinical concept. It included mental illness and any type of psychosocial incapacity, including reversible conditions. [302] Dementia at this time simply referred to anyone who had lost the ability to reason, and was applied equally to psychosis, "organic" diseases like syphilis that destroy the brain, and to the dementia associated with old age, which was attributed to "hardening of the arteries".

A 19th-century drawing of a woman diagnosed with dementia A woman diagnosed as suffering from chronic dementia. Colour Wellcome L0026688.jpg
A 19th-century drawing of a woman diagnosed with dementia

Dementia has been referred to in medical texts since antiquity. One of the earliest known allusions to dementia is attributed to the 7th-century BC Greek philosopher Pythagoras, who divided the human lifespan into six distinct phases: 0–6 (infancy), 7–21 (adolescence), 22–49 (young adulthood), 50–62 (middle age), 63–79 (old age), and 80–death (advanced age). The last two he described as the "senium", a period of mental and physical decay, and that the final phase was when "the scene of mortal existence closes after a great length of time that very fortunately, few of the human species arrive at, where the mind is reduced to the imbecility of the first epoch of infancy". [303] In 550 BC, the Athenian statesman and poet Solon argued that the terms of a man's will might be invalidated if he exhibited loss of judgement due to advanced age. Chinese medical texts made allusions to the condition as well, and the characters for "dementia" translate literally to "foolish old person". [304]

Athenian philosophers Aristotle and Plato discussed the mental decline that can come with old age and predicted that this affects everyone who becomes old and nothing can be done to stop this decline from taking place. Plato specifically talked about how the elderly should not be in positions that require responsibility because, "There is not much acumen of the mind that once carried them in their youth, those characteristics one would call judgement, imagination, power of reasoning, and memory. They see them gradually blunted by deterioration and can hardly fulfill their function." [305]

For comparison, the Roman statesman Cicero held a view much more in line with modern-day medical wisdom that loss of mental function was not inevitable in the elderly and "affected only those old men who were weak-willed". He spoke of how those who remained mentally active and eager to learn new things could stave off dementia. However, Cicero's views on aging, although progressive, were largely ignored in a world that would be dominated for centuries by Aristotle's medical writings. Physicians during the Roman Empire, such as Galen and Celsus, simply repeated the beliefs of Aristotle while adding few new contributions to medical knowledge.

Byzantine physicians sometimes wrote of dementia. It is recorded that at least seven emperors whose lifespans exceeded 70 years displayed signs of cognitive decline. In Constantinople, special hospitals housed those diagnosed with dementia or insanity, but these did not apply to the emperors, who were above the law and whose health conditions could not be publicly acknowledged.

Otherwise, little is recorded about dementia in Western medical texts for nearly 1700 years. One of the few references was the 13th-century friar Roger Bacon, who viewed old age as divine punishment for original sin. Although he repeated existing Aristotelian beliefs that dementia was inevitable, he did make the progressive assertion that the brain was the center of memory and thought rather than the heart.

Poets, playwrights, and other writers made frequent allusions to the loss of mental function in old age. William Shakespeare notably mentions it in the plays Hamlet and King Lear .

During the 19th century, doctors generally came to believe that elderly dementia was the result of cerebral atherosclerosis, although opinions fluctuated between the idea that it was due to blockage of the major arteries supplying the brain or small strokes within the vessels of the cerebral cortex.

In 1907, Bavarian psychiatrist Alois Alzheimer was the first to identify and describe the characteristics of progressive dementia in the brain of 51-year-old Auguste Deter. [306] Deter had begun to behave uncharacteristically, including accusing her husband of adultery, neglecting household chores, exhibiting difficulties writing and engaging in conversations, heightened insomnia, and loss of directional sense. [307] At one point, Deter was reported to have "dragged a bed sheet outside, wandered around wildly, and cried for hours at midnight". [307] Alzheimer began treating Deter when she entered a Frankfurt mental hospital on November 25, 1901. [307] During her ongoing treatment, Deter and her husband struggled to afford the cost of the medical care, and Alzheimer agreed to continue her treatment in exchange for Deter's medical records and donation of her brain upon death. [307] Deter died on April 8, 1906, after succumbing to sepsis and pneumonia. [307] Alzheimer conducted the brain biopsy using the Bielschowsky stain method, which was a new development at the time, and he observed senile plaques, neurofibrillary tangles, and atherosclerotic alteration. [306] At the time, the consensus among medical doctors had been that senile plaques were generally found in older patients, and the occurrence of neurofibrillary tangles was an entirely new observation at the time. [307] Alzheimer presented his findings at the 37th psychiatry conference of southwestern Germany in Tübingen on April 11, 1906; however, the information was poorly received by his peers. [307] By 1910, Alois Alzheimer's teacher, Emil Kraepelin, published a book in which he coined the term "Alzheimer's disease" in an attempt to acknowledge the importance of Alzheimer's discovery. [306] [307]

By the 1960s, the link between neurodegenerative diseases and age-related cognitive decline had become more established. By the 1970s, the medical community maintained that vascular dementia was rarer than previously thought and Alzheimer's disease caused the vast majority of old age mental impairments. More recently however, it is believed that dementia is often a mixture of conditions.

In 1976, neurologist Robert Katzmann suggested a link between senile dementia and Alzheimer's disease. [308] Katzmann suggested that much of the senile dementia occurring (by definition) after the age of 65, was pathologically identical with Alzheimer's disease occurring in people under age 65 and therefore should not be treated differently. [309] Katzmann thus suggested that Alzheimer's disease, if taken to occur over age 65, is actually common, not rare, and was the fourth- or 5th-leading cause of death, even though rarely reported on death certificates in 1976.

A helpful finding was that although the incidence of Alzheimer's disease increased with age (from 5–10% of 75-year-olds to as many as 40–50% of 90-year-olds), no threshold was found by which age all persons developed it. This is shown by documented supercentenarians (people living to 110 or more) who experienced no substantial cognitive impairment. Some evidence suggests that dementia is most likely to develop between ages 80 and 84 and individuals who pass that point without being affected have a lower chance of developing it.[ citation needed ] Women account for a larger percentage of dementia cases than men. [310] This can be attributed in part to their longer overall lifespan and greater odds of attaining an age where the condition is likely to occur. [311]

Much like other diseases associated with aging, dementia was comparatively rare before the 20th century, because few people lived past 80. Conversely, syphilitic dementia was widespread in the developed world until it was largely eradicated by the use of penicillin after World War II. With significant increases in life expectancy thereafter, the number of people over 65 started rapidly climbing. While elderly persons constituted an average of 3–5% of the population prior to 1945, by 2010 many countries reached 10–14% and in Germany and Japan, this figure exceeded 20%. Public awareness of Alzheimer's Disease greatly increased in 1994 when former US president Ronald Reagan announced that he had been diagnosed with the condition.

In the 21st century, other types of dementia were differentiated from Alzheimer's disease and vascular dementias (the most common types). This differentiation is on the basis of pathological examination of brain tissues, by symptomatology, and by different patterns of brain metabolic activity in nuclear medical imaging tests such as SPECT and PET scans of the brain. The various forms have differing prognoses and differing epidemiologic risk factors.

Terminology

Dementia in the elderly was once called senile dementia or senility which are now outdated terms. The condition was viewed as a normal and somewhat inevitable aspect of aging. [312]

By 1913–20 the term dementia praecox was introduced to suggest the development of senile-type dementia at a younger age. Eventually the two terms fused, so that until 1952 physicians used the terms dementia praecox (precocious dementia) and schizophrenia interchangeably. Since then, science has determined that dementia and schizophrenia are two different disorders, though they share some similarities.[ citation needed ] The term precocious dementia for a mental illness suggested that a type of mental illness like schizophrenia (including paranoia and decreased cognitive capacity) could be expected to arrive normally in all persons with greater age (see paraphrenia). After about 1920, the beginning use of dementia for what is now understood as schizophrenia and senile dementia helped limit the word's meaning to "permanent, irreversible mental deterioration". This began the change to the later use of the term and researchers have seen a connection between those diagnosed with schizophrenia and patients who are diagnosed with dementia, finding a positive correlation between the two diseases. [313]

The view that dementia must always be the result of a particular disease process led for a time to the proposed diagnosis of "senile dementia of the Alzheimer's type" (SDAT) in persons over the age of 65, with "Alzheimer's disease" diagnosed in persons younger than 65 who had the same pathology. Eventually, however, it was agreed that the age limit was artificial, and that Alzheimer's disease was the appropriate term for persons with that particular brain pathology, regardless of age.[ citation needed ]

After 1952, mental illnesses including schizophrenia were removed from the category of organic brain syndromes , and thus (by definition) removed from possible causes of "dementing illnesses" (dementias). At the same, however, the traditional cause of senile dementia – "hardening of the arteries" – now returned as a set of dementias of vascular cause (small strokes). These were now termed multi-infarct dementias or vascular dementias .[ citation needed ]

Society and culture

Dementia impacts not only individuals with dementia, but also their carers and the wider society. Among people aged 60 years and over, dementia is ranked the 9th most burdensome condition according to the 2010 Global Burden of Disease (GBD) estimates. [270]

The societal cost of dementia is high, especially for caregivers. [314] According to research conducted in the UK, almost two out of three carers of people with dementia feel lonely. Most of the carers in the study were family members or friends. [315] [316] Family carers of people with dementia are at higher risk of developing psychological and physical conditions. [317]

National policies on dementia

The World Health Organization's (WHO) global action plan on the public health response to dementia (2017-2025) set a target for 75% of WHO Member States (194 countries) to develop a policy or plan for dementia by 2025. These plans recognize that people can live well with dementia for years, as long as the right support and timely access to a diagnosis are available. However, in 2025, only 23% of Member States (45 countries) have a national policy for dementia. [318]

Financial costs

The financial costs of care in people with dementia are high and tend to increase toward death. Long-term care facility and informal care costs are among the highest cost components, while non-White ethnicity, female sex, married status, higher education level, more severe dementia, and higher number of chronic conditions are associated with higher costs. [317]

The global costs of dementia was around US$818 billion in 2015, a 35.4% increase from US$604 billion in 2010. [270] By 2050 the estimated global cost will be $9.12 trillion. [319]

In 2015, the annual cost per person with Alzheimer's in the United States was around $19,144.36. [317] The total costs for the country was estimated to be about $167.74 billion. By 2030, it is predicted the annual socioeconomic cost will total to about $507 billion, and by 2050 that number is expected to reach $1.89 trillion. [319]

The total cost of dementia care in the UK is projected to increase by 172%, from £34.7 billion in 2019 to £94.1 billion in 2040. [317]

The estimated costs of dementia in low- and middle-income countries (LMICs) are lower compared to high-income countries, with indirect costs making up the largest proportion in LMICs. However, these estimates are likely an underrepresentation, as there have been limited research studies on dementia costs in LMICs, particularly low-income countries. [320] [321]

Awareness

A worldwide study in 2019 showed that about 66% of the general public believe that dementia is a normal part of aging, and not a disorder, and 62% of healthcare professionals also held this view. [322] A follow-up study in 2024 showed that this figure had increased to 80% in the general public and to 65% among healthcare workers. [323] In 2022, only 42% of surveyed public in England knew that dementia is a terminal condition, and over 90% were unaware that dementia was the leading cause of cause of death in their country. [324] There is also persistent stigma, which can be a barrier for people seeking help for dementia and accessing care. [323] [325] In 2024 88% of people living with dementia reported experiencing discrimination, an increase of 5% from 2019. [323] Over 64% of the general public believe people with dementia are impulsive and unpredictable. [323]

Celebrities have used their platforms to raise awareness for the different forms of dementia and the need for further support, including former First Lady of California Maria Shriver, [326] actor Samuel L. Jackson, editor-in-chief of ELLE Magazine Nina Garcia, professional skateboarder Tony Hawk, and others. [327] Additional dementia awareness has been raised through the diagnoses of high-profile persons themselves, including actors Bruce Willis (diagnosed with frontotemporal dementia) [328] and Robin Williams (diagnosis of dementia with Lewy bodies), [329] actress and pin-up model Rita Hayworth, [330] activist Rosa Parks, [331] former US President Ronald Reagan, [332] TV host Wendy Williams, [333] musicians Tony Bennett [334] and Maureen McGovern. [335]

Philanthropy

In 2015, Atlantic Philanthropies announced a $177 million gift aimed at understanding and reducing dementia. The recipient was the Global Brain Health Institute, a program co-led by the University of California, San Francisco and Trinity College Dublin. [336]

In October 2020, the Caretaker's (James Leyland Kirby) last music release, Everywhere at the End of Time , was popularized by TikTok users for its depiction of the stages of dementia. Kirby said that the use of the recordings could cause empathy among a younger public. [337]

On November 2, 2020, Scottish billionaire Tom Hunter donated £1 million, split between Alzheimer's society, and Music for dementia. This donation was prompted after watching a former music teacher with dementia, Paul Harvey, playing one of his own compositions on the piano in a video. [338]

Research directions

Artificial intelligence, and machine learning algorithms have the potential to improve early diagnosis and treatment planning for dementia. [339]

Co-production is "a collaborative approach that prioritises equity, shared power and responsibility among all partners in a safe space". It helps to ensure research is inclusive and meaningful, with potential to inform policy and practice. [340]

Efforts to facilitate research with people living with dementia include the development of the Dementia Enquirers Gold Standards for Co-Research and Ethical Research, [341] [342] and evidence-informed guidelines to involve people in research who have impaired mental capacity and are nearing the end of life. [343] There are also dedicated networks such as the UK-based EMPOWER Dementia Network+, which uses a co-productive approach to engage and include people from underrepresented communities to tackle inequalities in dementia care and research. [344] [345]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Dementia". www.who.int. Retrieved January 13, 2026.
  2. Emmady PD, Schoo C, Tadi P (2025). "Major Neurocognitive Disorder (Dementia)". StatPearls. StatPearls Publishing. Retrieved January 13, 2026.
  3. 1 2 3 4 5 6 7 8 Livingston G, Huntley J, Liu KY, et al. (July 31, 2024). "Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission". The Lancet. 404 (10452): 572–628. Bibcode:2024Lanc..404..572L. doi:10.1016/S0140-6736(24)01296-0. PMID   39096926.
  4. 1 2 Creavin ST, Wisniewski S, Noel-Storr AH, et al. (January 2016). "Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations". The Cochrane Database of Systematic Reviews. 2016 (1) CD011145. doi:10.1002/14651858.CD011145.pub2. hdl: 1983/00876aeb-2061-43f5-b7e1-938c666030ab . PMC   8812342 . PMID   26760674.
  5. "Differential diagnosis dementia". NICE. Retrieved January 20, 2022.
  6. 1 2 3 4 5 6 7 Arvanitakis Z, Shah RC, Bennett DA (October 22, 2019). "Diagnosis and Management of Dementia: Review". JAMA. 322 (16): 1589–1599. Bibcode:2019JAMA..322.1589A. doi:10.1001/jama.2019.4782. ISSN   0098-7484. PMC   7462122 . PMID   31638686.
  7. 1 2 Li Z, Yang N, He L, et al. (August 2024). "Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study". The Journal of Prevention of Alzheimer's Disease. 11 (4): 1013–1021. doi: 10.14283/jpad.2024.21 . PMC   12275824 . PMID   39044512.
  8. 1 2 "What Is Dementia? Symptoms, Types, and Diagnosis". National Institute on Aging. December 8, 2022. Retrieved January 26, 2026.
  9. 1 2 3 4 Bathini P, Brai E, Auber LA (November 2019). "Olfactory dysfunction in the pathophysiological continuum of dementia" (PDF). Ageing Research Reviews. 55 100956. doi:10.1016/j.arr.2019.100956. PMID   31479764. S2CID   201742825.
  10. "ICD-11 for Mortality and Morbidity Statistics". icd.who.int. Archived from the original on August 1, 2018. Retrieved January 20, 2022.
  11. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). Washington, DC: American Psychiatric Association. pp.  591–603. ISBN   978-0-89042-554-1.
  12. 1 2 3 4 5 "Dementias | National Institute of Neurological Disorders and Stroke". www.ninds.nih.gov. Retrieved January 20, 2026.
  13. 1 2 Wilson H, Pagano G, Politis M (March 2019). "Dementia spectrum disorders: lessons learnt from decades with PET research". J Neural Transm (Vienna). 126 (3): 233–251. doi:10.1007/s00702-019-01975-4. PMC   6449308 . PMID   30762136.
  14. 1 2 3 4 "Mixed dementia". Dementia UK. Retrieved January 14, 2026.
  15. Vila-Castelar C, Fox-Fuller JT, Guzmán-Vélez E, et al. (March 8, 2022). "A cultural approach to dementia – insights from US Latino and other minoritized groups". Nature Reviews Neurology. 18 (5): 307–314. doi:10.1038/s41582-022-00630-z. ISSN   1759-4758. PMC   9113534 . PMID   35260817.
  16. 1 2 Lin JS, O'Connor E, Rossom RC, et al. (November 2013). "Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 159 (9): 601–612. doi: 10.7326/0003-4819-159-9-201311050-00730 . PMID   24145578.
  17. 1 2 "Dementia remains UK's top cause of death". Dementia UK. October 19, 2023. Retrieved January 19, 2026.
  18. Vedel I, Sheets D, McAiney C, et al. (2020). "CCCDTD5: Individual and community-based psychosocial and other non-pharmacological interventions to support persons living with dementia and their caregivers". Alzheimers Dement (N Y). 6 (1) e12086. doi:10.1002/trc2.12086. PMC   7657138 . PMID   33209973.
  19. 1 2 Browne B, Kupeli N, Moore KJ, et al. (June 17, 2021). "Defining end of life in dementia: A systematic review". Palliative Medicine. 35 (10): 1733–1746. doi:10.1177/02692163211025457. ISSN   0269-2163. PMC   8637358 . PMID   34137314.
  20. Orgeta V, Leung P, Del-Pino-Casado R, et al. (April 2022). "Psychological treatments for depression and anxiety in dementia and mild cognitive impairment". The Cochrane Database of Systematic Reviews. 2022 (4) CD009125. doi:10.1002/14651858.CD009125.pub3. PMC   9035877 . PMID   35466396.
  21. "What Is Dementia? | CDC". cdc.gov. December 19, 2019. Retrieved October 3, 2022.
  22. "Dementia – Signs and Symptoms". American Speech Language D Association.
  23. Ayalon L (November 13, 2006). "Effectiveness of Nonpharmacological Interventions for the Management of Neuropsychiatric Symptoms in Patients With Dementia: A Systematic Review" . Archives of Internal Medicine. 166 (20): 2182–2188. doi:10.1001/archinte.166.20.2182. ISSN   0003-9926. PMID   17101935.
  24. Cohen-Mansfield J (September 2001). "Nonpharmacologic Interventions for Inappropriate Behaviors in Dementia: A Review, Summary, and Critique" . The American Journal of Geriatric Psychiatry. 9 (4): 361–381. doi:10.1097/00019442-200111000-00005. PMID   11739063.
  25. Tampi RR, Jeste DV (August 1, 2022). "Dementia Is More Than Memory Loss: Neuropsychiatric Symptoms of Dementia and Their Nonpharmacological and Pharmacological Management" . American Journal of Psychiatry. 179 (8): 528–543. doi:10.1176/appi.ajp.20220508. ISSN   0002-953X. PMID   35921394.
  26. Terracciano A, Luchetti M, Karakose S, et al. (August 5, 2025). "Meta-analyses of personality change from the preclinical to the clinical stages of dementia". Ageing Research Reviews. 112 102852. doi:10.1016/j.arr.2025.102852. PMC   12358811 . PMID   40752776.
  27. "Continence, dementia, and care that preserves dignity" . NIHR Evidence. June 21, 2022. doi:10.3310/nihrevidence_51255. S2CID   251785991.
  28. Cipriani G, Carlesi C, Lucetti C, et al. (December 2016). "Eating Behaviors and Dietary Changes in Patients With Dementia". American Journal of Alzheimer's Disease & Other Dementias. 31 (8): 706–716. doi:10.1177/1533317516673155. ISSN   1533-3175. PMC   10852764 . PMID   27756815.
  29. Helvik AS, Bergh S, Tevik K (October 10, 2023). "A systematic review of prevalence of pain in nursing home residents with dementia". BMC Geriatrics. 23 (1): 641. doi: 10.1186/s12877-023-04340-z . ISSN   1471-2318. PMC   10566134 . PMID   37817061.
  30. "Dementia: comorbidities in patients – data briefing". GOV.UK. Retrieved November 22, 2020.
  31. Waite SJ, Maitland S, Thomas A, et al. (January 2021). "Sarcopenia and frailty in individuals with dementia: A systematic review" . Archives of Gerontology and Geriatrics. 92 104268. doi:10.1016/j.archger.2020.104268. PMID   33011431.
  32. "Early stages of dementia: symptoms, diagnosis and treatment". Dementia UK. Retrieved January 18, 2026.
  33. 1 2 3 4 5 6 "Understanding the Seven Stages of Dementia". NCCDP. May 30, 2025. Retrieved January 18, 2026.
  34. "Seven Stages of Dementia | Symptoms, Progression & Durations" . Retrieved December 19, 2020.
  35. 1 2 "Brief cognitive rating scale" (PDF). aptageriatrics. Retrieved January 18, 2026.
  36. 1 2 Sheehan B (November 2012). "Assessment scales in dementia". Therapeutic Advances in Neurological Disorders. 5 (6): 349–358. doi:10.1177/1756285612455733. PMC   3487532 . PMID   23139705.
  37. "RUDAS scale" (PDF). cambridge.org. Retrieved January 19, 2026.
  38. Bhatia-Dey N, Heinbockel T (June 2021). "The Olfactory System as Marker of Neurodegeneration in Aging, Neurological and Neuropsychiatric Disorders". Int J Environ Res Public Health. 18 (13): 6976. doi: 10.3390/ijerph18136976 . PMC   8297221 . PMID   34209997.
  39. Boesveldt S, Parma V (January 2021). "The importance of the olfactory system in human well-being, through nutrition and social behavior". Cell Tissue Res. 383 (1): 559–567. doi:10.1007/s00441-020-03367-7. PMC   7802608 . PMID   33433688.
  40. 1 2 Breton A, Casey D, Arnaoutoglou NA (February 2019). "Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies". International Journal of Geriatric Psychiatry. 34 (2): 233–242. doi:10.1002/gps.5016. PMID   30370616. S2CID   53097138.
  41. Atri A (March 2019). "The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management". Med Clin North Am. 103 (2): 263–293. doi: 10.1016/j.mcna.2018.10.009 . PMID   30704681.
  42. 1 2 Hugo J, Ganguli M (August 2014). "Dementia and cognitive impairment: epidemiology, diagnosis, and treatment". Clinics in Geriatric Medicine. 30 (3): 421–442. doi:10.1016/j.cger.2014.04.001. PMC   4104432 . PMID   25037289.
  43. 1 2 "Dementia and end of life planning". nhs.uk. August 18, 2023. Retrieved January 25, 2026.
  44. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). Washington, DC: American Psychiatric Association. pp.  591–603. ISBN   978-0-89042-554-1.
  45. Cervenka I, Agudelo LZ, Ruas JL (July 2017). "Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health". Science. 357 (6349) eaaf9794. Bibcode:2017Sci...357f9794C. doi: 10.1126/science.aaf9794 . PMID   28751584.
  46. Solvang SH, Nordrehaug JE, Aarsland D, et al. (2019). "Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia". Int J Tryptophan Res. 12 1178646919877883. doi:10.1177/1178646919877883. PMC   6769202 . PMID   31632053.
  47. Jenkins C, Ginesi L, Keenan B (2016). Dementia care at a glance. Chichester, West Sussex: John Wiley & Sons. ISBN   978-1-118-85998-8. OCLC   905089525.
  48. Rohrer JD, Knight WD, Warren JE, et al. (January 2008). "Word-finding difficulty: a clinical analysis of the progressive aphasias". Brain. 131 (Pt 1): 8–38. doi:10.1093/brain/awm251. PMC   2373641 . PMID   17947337.
  49. Islam M, Mazumder M, Schwabe-Warf D, et al. (February 2019). "Personality Changes With Dementia From the Informant Perspective: New Data and Meta-Analysis". Journal of the American Medical Directors Association. 20 (2): 131–137. doi:10.1016/j.jamda.2018.11.004. PMC   6432780 . PMID   30630729.
  50. "Diagnosing Lewy Body Dementia". National Institute on Aging. Archived from the original on August 1, 2017. Retrieved May 10, 2020.
  51. 1 2 3 4 5 6 7 8 9 Budson A, Solomon P (2011). Memory loss: a practical guide for clinicians. [Edinburgh?]: Elsevier Saunders. ISBN   978-1-4160-3597-8.
  52. Gallingani C, Tondelli M, Vannini P, et al. (2025). "The association between anosognosia and neuropsychiatric symptoms in neurodegenerative dementias: a narrative review". Front Neurol. 16: 1649627. doi:10.3389/fneur.2025.1649627. PMC   12511066 . PMID   41079349.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
  53. Payne M, Morley JE (May 1, 2018). "Editorial: Dysphagia, Dementia and Frailty". The Journal of Nutrition, Health & Aging. 22 (5): 562–565. doi: 10.1007/s12603-018-1033-5 . PMID   29717753. S2CID   13753522.
  54. Della Sala S, Spinnler H, Venneri A (February 2004). "Walking difficulties in patients with Alzheimer's disease might originate from gait apraxia" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 75 (2): 196–201. PMC   1738895 . PMID   14742586. Archived (PDF) from the original on October 9, 2022.
  55. Mc Ardle R, Galna B, Donaghy P, et al. (October 2019). "Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?". Alzheimer's & Dementia. 15 (10): 1367–1377. doi: 10.1016/j.jalz.2019.06.4953 . PMID   31548122.
  56. "Mental, physical and speech abilities in later stages of dementia". Alzheimer's Society. June 29, 2022. Retrieved July 30, 2022.
  57. Mashour GA, Frank L, Batthyany A, et al. (August 2019). "Paradoxical lucidity: A potential paradigm shift for the neurobiology and treatment of severe dementias". Alzheimer's & Dementia. 15 (8): 1107–1114. doi: 10.1016/j.jalz.2019.04.002 . hdl: 2027.42/153062 . PMID   31229433.
  58. Chung CG, Lee H, Lee SB (September 2018). "Mechanisms of protein toxicity in neurodegenerative diseases". Cell Mol Life Sci. 75 (17): 3159–3180. doi:10.1007/s00018-018-2854-4. PMC   6063327 . PMID   29947927.
  59. Mouta S, Fonseca Vaz I, Pires M, et al. (2023). "What do we know about pseudodementia?". Gen Psychiatr. 36 (4) e100939. doi:10.1136/gpsych-2022-100939. PMC   10445398 . PMID   37622032.
  60. Abyadeh M, Gupta V, Chitranshi N, et al. (April 2021). "Mitochondrial dysfunction in Alzheimer's disease – a proteomics perspective". Expert Review of Proteomics. 18 (4): 295–304. doi:10.1080/14789450.2021.1918550. PMID   33874826. S2CID   233310698.
  61. Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". The Journal of Clinical Psychiatry. 64 (Suppl 9): 7–10. PMID   12934968.
  62. Angelopoulou E, Paudel YN, Shaikh MF, et al. (March 2020). "Flotillin: A Promising Biomarker for Alzheimer's Disease". J Pers Med. 10 (2): 20. doi: 10.3390/jpm10020020 . PMC   7354424 . PMID   32225073.
  63. Huber H, Montoliu-Gaya L, Brum WS (January 5, 2026). "A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology". Nature Medicine. doi: 10.1038/s41591-025-04080-0 . PMID   41491101.
  64. 1 2 Iadecola C (November 2013). "The pathobiology of vascular dementia". Neuron. 80 (4): 844–866. doi:10.1016/j.neuron.2013.10.008. PMC   3842016 . PMID   24267647.
  65. Baskys A, Cheng JX (November 2012). "Pharmacological prevention and treatment of vascular dementia: approaches and perspectives". Exp Gerontol. 47 (11): 887–891. doi:10.1016/j.exger.2012.07.002. PMID   22796225. S2CID   1153876.
  66. "Vascular dementia – Symptoms and causes". Mayo Clinic. Retrieved July 8, 2021.
  67. Abdelmoaty MM, Lu E, Kadry R, et al. (November 2023). "Clinical biomarkers for Lewy body diseases". Cell Biosci. 13 (1) 209. doi: 10.1186/s13578-023-01152-x . PMC   10644566 . PMID   37964309.
  68. McKeith IG, Ferman TJ, Thomas AJ, et al. (April 2020). "Research criteria for the diagnosis of prodromal dementia with Lewy bodies". Neurology. 94 (17): 743–755. doi:10.1212/WNL.0000000000009323. PMC   7274845 . PMID   32241955.
  69. Jurek L, Herrmann M, Bonze M, et al. (March 1, 2018). "Behavioral and psychological symptoms in Lewy body disease: a review". Gériatrie et Psychologie Neuropsychiatrie du Vieillissement. 16 (1): 87–95. doi:10.1684/pnv.2018.0723. PMID   29569570.
  70. 1 2 3 4 McKeith IG, Boeve BF, Dickson DW, et al. (July 2017). "Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium". Neurology (Review). 89 (1): 88–100. doi:10.1212/WNL.0000000000004058. PMC   5496518 . PMID   28592453.
  71. 1 2 3 Taylor JP, McKeith IG, Burn DJ, et al. (February 2020). "New evidence on the management of Lewy body dementia". Lancet Neurol (Review). 19 (2): 157–169. doi:10.1016/S1474-4422(19)30153-X. PMC   7017451 . PMID   31519472. Courtesty link available here. Archived July 3, 2020, at the Wayback Machine
  72. Finger EC (April 2016). "Frontotemporal Dementias". Continuum. 22 (2 Dementia): 464–489. doi:10.1212/CON.0000000000000300. PMC   5390934 . PMID   27042904.
  73. Bateman DR, Gill S, Hu S, et al. (2020). "Agitation and impulsivity in mid and late life as possible risk markers for incident dementia". Alzheimer's & Dementia: Translational Research & Clinical Interventions. 6 (1) e12016. doi:10.1002/trc2.12016. PMC   7507499 . PMID   32995467.
  74. 1 2 3 4 5 "Frontotemporal Disorders: Causes, Symptoms, and Diagnosis". National Institute on Aging. January 22, 2025. Retrieved January 24, 2026.
  75. Taylor B, Bocchetta M, Shand C, et al. (March 2025). "Data-driven neuroanatomical subtypes of primary progressive aphasia". Brain. 148 (3): 955–968. doi:10.1093/brain/awae314. PMC   11884653 . PMID   39374849.
  76. Hansen N (March 2025). "Update on autoimmune dementia and its precursors". Behav Brain Res. 482 115460. doi:10.1016/j.bbr.2025.115460. PMID   39889830.
  77. 1 2 Sechi E, Flanagan EP (February 2019). "Diagnosis and Management of Autoimmune Dementia". Curr Treat Options Neurol. 21 (3): 11. doi:10.1007/s11940-019-0550-9. PMID   30809732.
  78. Elvidge KL, Christodoulou J, Farrar MA, et al. (November 2023). "The collective burden of childhood dementia: a scoping review". Brain. 146 (11): 4446–4455. doi:10.1093/brain/awad242. PMC   10629766 . PMID   37471493.
  79. 1 2 Gale SA, Acar D, Daffner KR (October 2018). "Dementia". Am J Med. 131 (10): 1161–1169. doi:10.1016/j.amjmed.2018.01.022. PMID   29425707. S2CID   240122313.
  80. "What causes young-onset dementia? | Alzheimer's Society". alzheimers.org.uk. Retrieved January 10, 2022.
  81. Masters CL, Bateman R, Blennow K, et al. (October 2015). "Alzheimer's disease". Nature Reviews. Disease Primers. 1 15056. doi:10.1038/nrdp.2015.56. PMID   27188934. S2CID   20844163.
  82. "What Is Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)?". National Institute on Aging. February 24, 2023. Retrieved January 27, 2026.
  83. McKee AC, Stein TD, Huber BR, et al. (April 2023). "Chronic traumatic encephalopathy (CTE): criteria for neuropathological diagnosis and relationship to repetitive head impacts". Acta Neuropathol. 145 (4): 371–394. doi:10.1007/s00401-023-02540-w. PMC   10020327 . PMID   36759368.
  84. Frank S (January 2014). "Treatment of Huntington's disease". Neurotherapeutics. 11 (1): 153–160. doi:10.1007/s13311-013-0244-z. PMC   3899480 . PMID   24366610.
  85. 1 2 "HIV-Associated Dementia – Neurologic Disorders". MSD Manual Professional Edition.
  86. Gray F, Adle-Biassette H, Chretien F, et al. (2001). "Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments". Clinical Neuropathology. 20 (4): 146–155. PMID   11495003.
  87. Gao LP, Tian TT, Xiao K, et al. (2024). "Updated global epidemiology atlas of human prion diseases". Front Public Health. 12: 1411489. doi:10.3389/fpubh.2024.1411489. PMID   38939567.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
  88. Nunes PT, Kipp BT, Reitz NL, et al. (2019). "Aging with alcohol-related brain damage: Critical brain circuits associated with cognitive dysfunction". Late Aging Associated Changes in Alcohol Sensitivity, Neurobehavioral Function, and Neuroinflammation. International Review of Neurobiology. Vol. 148. pp. 101–168. doi:10.1016/bs.irn.2019.09.002. ISBN   978-0-12-817530-9. PMC   7372724 . PMID   31733663.
  89. 1 2 3 Zis P, Hadjivassiliou M (February 26, 2019). "Treatment of Neurological Manifestations of Gluten Sensitivity and Coeliac Disease". Curr Treat Options Neurol (Review). 21 (3) 10. doi: 10.1007/s11940-019-0552-7 . PMID   30806821.
  90. 1 2 Martin S, Kelly S, Khan A, et al. (June 2015). "Attitudes and preferences towards screening for dementia: a systematic review of the literature". BMC Geriatr. 15 66. doi: 10.1186/s12877-015-0064-6 . PMC   4469007 . PMID   26076729.
  91. "Dementia definition". MDGuidelines. Reed Group. Archived from the original on June 29, 2009. Retrieved June 4, 2009.
  92. Caplan JP, Rabinowitz T (November 2010). "An approach to the patient with cognitive impairment: delirium and dementia". The Medical Clinics of North America. 94 (6): 1103–1116, ix. doi:10.1016/j.mcna.2010.08.004. PMID   20951272.
  93. Gleason OC (March 2003). "Delirium". American Family Physician. 67 (5): 1027–1034. PMID   12643363. Archived from the original on September 29, 2007.
  94. Lai CK (2014). "The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders". Clinical Interventions in Aging. 9: 1051–1061. doi: 10.2147/CIA.S63504 . PMC   4099101 . PMID   25031530.
  95. Worrall L, Hickson LM (2003). "Implications for theory, practice, and policy". In Worrall LE, Hickson LM (eds.). Communication disability in aging: from prevention to intervention. Clifton Park, NY: Delmar Learning. pp. 297–298. ISBN   978-0-7693-0015-3.
  96. James C, Ranson JM, Everson R, et al. (December 2021). "Performance of Machine Learning Algorithms for Predicting Progression to Dementia in Memory Clinic Patients". JAMA Network Open. 4 (12): e2136553. doi:10.1001/jamanetworkopen.2021.36553. PMC   8678688 . PMID   34913981.
  97. Boustani M, Peterson B, Hanson L, et al. (June 2003). "Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 138 (11): 927–937. doi:10.7326/0003-4819-138-11-200306030-00015. PMID   12779304. S2CID   20779164.
  98. 1 2 Cullen B, O'Neill B, Evans JJ, et al. (August 2007). "A review of screening tests for cognitive impairment". Journal of Neurology, Neurosurgery, and Psychiatry. 78 (8): 790–799. doi:10.1136/jnnp.2006.095414. PMC   2117747 . PMID   17178826.
  99. Ranson JM, Kuźma E, Hamilton W, et al. (April 2019). "Predictors of dementia misclassification when using brief cognitive assessments". Neurology. Clinical Practice. 9 (2): 109–117. doi:10.1212/CPJ.0000000000000566. PMC   6461420 . PMID   31041124.
  100. Contador, I. et al. (2017) "Impact of literacy and years of education on the diagnosis of dementia:A population-based study," Journal of Clinical and Experimental Neuropsychology, 39(2), pp. 112–119. Available at: https://doi.org/10.1080/13803395.2016.1204992.
  101. Teng EL, Chui HC (August 1987). "The Modified Mini-Mental State (3MS) examination". The Journal of Clinical Psychiatry. 48 (8): 314–318. PMID   3611032.
  102. Teng EL, Hasegawa K, Homma A, et al. (1994). "The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia". International Psychogeriatrics. 6 (1): 45–58, discussion 62. doi: 10.1017/S1041610294001602 . PMID   8054493. S2CID   25322040.
  103. Tombaugh TN (March 2004). "Trail Making Test A and B: normative data stratified by age and education". Archives of Clinical Neuropsychology. 19 (2): 203–214. doi: 10.1016/S0887-6177(03)00039-8 . PMID   15010086.
  104. Nasreddine ZS, Phillips NA, Bédirian V, et al. (April 2005). "The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment". Journal of the American Geriatrics Society. 53 (4): 695–699. doi:10.1111/j.1532-5415.2005.53221.x. PMID   15817019. S2CID   9014589.
  105. Dawes P, Reeves D, Yeung WK, et al. (May 2023). "Development and validation of the Montreal cognitive assessment for people with hearing impairment (MoCA-H)". Journal of the American Geriatrics Society. 71 (5): 1485–1494. doi: 10.1111/jgs.18241 . PMID   36722180. S2CID   256457783.
  106. "How to identify dementia in people with hearing loss" . NIHR Evidence. February 8, 2023. doi: 10.3310/nihrevidence_59137 . S2CID   260465275.
  107. Hendry K, Green C, McShane R, et al. (March 2019). "AD-8 for detection of dementia across a variety of healthcare settings". The Cochrane Database of Systematic Reviews. 3 (3) CD011121. doi:10.1002/14651858.CD011121.pub2. PMC   6398085 . PMID   30828783.
  108. Bee P. "The five-minute test that can tell if you're on the road to dementia" . Retrieved January 1, 2022.
  109. 1 2 "FDA Clears 5-Minute Test for Early Dementia". Medscape. Retrieved January 1, 2022.
  110. Jorm AF (September 2004). "The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review". International Psychogeriatrics. 16 (3): 275–293. doi: 10.1017/S1041610204000390 . PMID   15559753. S2CID   145256616.
  111. Burton JK, Stott DJ, McShane R, et al. (July 2021). "Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early detection of dementia across a variety of healthcare settings". The Cochrane Database of Systematic Reviews. 2021 (7) CD011333. doi:10.1002/14651858.CD011333.pub3. PMC   8406787 . PMID   34275145.
  112. Jacova C, Kertesz A, Blair M, et al. (October 2007). "Neuropsychological testing and assessment for dementia". Alzheimer's & Dementia. 3 (4): 299–317. doi:10.1016/j.jalz.2007.07.011. PMID   19595951. S2CID   40462470.
  113. Chouliaras L, O'Brien JT (October 2023). "The use of neuroimaging techniques in the early and differential diagnosis of dementia". Mol Psychiatry. 28 (10): 4084–4097. doi:10.1038/s41380-023-02215-8. PMC   10827668 . PMID   37608222.
  114. Bonte FJ, Harris TS, Hynan LS, et al. (July 2006). "Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation". Clinical Nuclear Medicine. 31 (7): 376–378. doi:10.1097/01.rlu.0000222736.81365.63. PMID   16785801. S2CID   39518497.
  115. Dougall NJ, Bruggink S, Ebmeier KP (2004). "Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia" (PDF). The American Journal of Geriatric Psychiatry. 12 (6): 554–570. doi:10.1176/appi.ajgp.12.6.554. PMID   15545324. S2CID   12375536. Archived from the original (PDF) on July 13, 2020.
  116. 1 2 Livingston G, Huntley J, Sommerlad A, et al. (August 2020). "Dementia prevention, intervention, and care: 2020 report of the Lancet Commission". Lancet. 396 (10248): 413–446. doi:10.1016/S0140-6736(20)30367-6. PMC   7392084 . PMID   32738937.
  117. Zhang YR, Xu W, Zhang W, et al. (October 2022). "Modifiable risk factors for incident dementia and cognitive impairment: An umbrella review of evidence". J Affect Disord. 314: 160–167. doi:10.1016/j.jad.2022.07.008. PMID   35863541.
  118. Zhang YR, Xu W, Zhang W, et al. (October 2022). "Modifiable risk factors for incident dementia and cognitive impairment: An umbrella review of evidence". J Affect Disord. 314: 160–167. doi:10.1016/j.jad.2022.07.008. PMID   35863541.
  119. 1 2 Huang X, Steinmetz J, Marsh EK, et al. (May 2025). "A systematic review with a Burden of Proof meta-analysis of health effects of long-term ambient fine particulate matter (PM2.5) exposure on dementia". Nature Aging. 5 (5): 897–908. doi:10.1038/s43587-025-00844-y. ISSN   2662-8465. PMC   12092285 . PMID   40119171.
  120. Ding J, Davis-Plourde KL, Sedaghat S, et al. (January 2020). "Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies". The Lancet. Neurology. 19 (1): 61–70. doi:10.1016/S1474-4422(19)30393-X. PMC   7391421 . PMID   31706889.
  121. Lourida I, Hannon E, Littlejohns TJ, et al. (July 2019). "Association of Lifestyle and Genetic Risk With Incidence of Dementia". JAMA. 322 (5): 430–437. doi:10.1001/jama.2019.9879. PMC   6628594 . PMID   31302669.
  122. Aschwanden D, Strickhouser JE, Luchetti M, et al. (May 2021). "Is personality associated with dementia risk? A meta-analytic investigation". Ageing Research Reviews. 67 101269. doi:10.1016/j.arr.2021.101269. PMC   8005464 . PMID   33561581.
  123. Sutin AR, Aschwanden D, Luchetti M, et al. (2021). "Sense of Purpose in Life Is Associated with Lower Risk of Incident Dementia: A Meta-Analysis". Journal of Alzheimer's Disease. 83 (1): 249–258. doi:10.3233/JAD-210364. PMC   8887819 . PMID   34275900.
  124. "Loneliness, but not social isolation, predicts development of dementia in older people" . NIHR Evidence (Plain English summary). May 27, 2020. doi:10.3310/alert_40330. S2CID   241649845.
  125. Rafnsson SB, Orrell M, d'Orsi E, et al. (January 2020). Carr D (ed.). "Loneliness, Social Integration, and Incident Dementia Over 6 Years: Prospective Findings From the English Longitudinal Study of Ageing". The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 75 (1): 114–124. doi:10.1093/geronb/gbx087. PMC   6909434 . PMID   28658937.
  126. 1 2 Cheng ST (September 2016). "Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities". Current Psychiatry Reports. 18 (9) 85. doi:10.1007/s11920-016-0721-2. PMC   4969323 . PMID   27481112.
  127. Yu RC, Proctor D, Soni J, et al. (July 1, 2024). "Adult-onset hearing loss and incident cognitive impairment and dementia – A systematic review and meta-analysis of cohort studies". Ageing Research Reviews. 98 102346. doi: 10.1016/j.arr.2024.102346 . ISSN   1568-1637. PMID   38788800.
  128. 1 2 "What impact does hearing loss have on dementia risk?". NIHR Evidence. February 19, 2025.
  129. 1 2 3 4 Panza F, Lozupone M, Sardone R, et al. (2019). "Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life". Therapeutic Advances in Chronic Disease. 10 2040622318811000. doi: 10.1177/2040622318811000 . PMC   6700845 . PMID   31452865.
  130. Thomson RS, Auduong P, Miller AT, et al. (April 2017). "Hearing loss as a risk factor for dementia: A systematic review". Laryngoscope Investigative Otolaryngology. 2 (2): 69–79. doi:10.1002/lio2.65. PMC   5527366 . PMID   28894825.
  131. Hubbard HI, Mamo SK, Hopper T (July 2018). "Dementia and Hearing Loss: Interrelationships and Treatment Considerations". Seminars in Speech and Language. 39 (3): 197–210. doi:10.1055/s-0038-1660779. PMID   29933487. S2CID   49383232.
  132. Ford AH, Hankey GJ, Yeap BB, et al. (June 2018). "Hearing loss and the risk of dementia in later life". Maturitas. 112: 1–11. doi:10.1016/j.maturitas.2018.03.004. PMID   29704910. S2CID   13998812.
  133. Fink HA, Jutkowitz E, McCarten JR, et al. (January 2018). "Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review". Annals of Internal Medicine. 168 (1): 39–51. doi:10.7326/M17-1529. PMID   29255847. S2CID   24193907.
  134. Hughes D, Judge C, Murphy R, et al. (May 2020). "Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis". JAMA. 323 (19): 1934–1944. doi:10.1001/jama.2020.4249. PMC   7237983 . PMID   32427305.
  135. Arapakis K, Brunner E, French E, et al. (October 2021). "Dementia and disadvantage in the USA and England: population-based comparative study". BMJ Open. 11 (10) e045186. doi: 10.1136/bmjopen-2020-045186 . PMC   8496387 . PMID   34615672.
  136. Mukadam N, Anderson R, Walsh S, et al. (September 1, 2024). "Benefits of population-level interventions for dementia risk factors: an economic modelling study for England". The Lancet Healthy Longevity. 5 (9) 100611. doi: 10.1016/S2666-7568(24)00117-X . ISSN   2666-7568. PMID   39096915.
  137. Daly B, Thompsell A, Sharpling J, et al. (January 2018). "Evidence summary: the relationship between oral health and dementia" (PDF). British Dental Journal. 223 (11): 846–853. doi:10.1038/sj.bdj.2017.992. PMID   29192686. S2CID   19633523.
  138. Miklossy J (2015). "Historic evidence to support a causal relationship between spirochetal infections and Alzheimer's disease". Frontiers in Aging Neuroscience. 7: 46. doi: 10.3389/fnagi.2015.00046 . PMC   4399390 . PMID   25932012.
  139. "Can poor oral health lead to dementia?". British Dental Journal. 223 (11): 840. December 2017. doi:10.1038/sj.bdj.2017.1064. PMID   29243693. S2CID   25898592.
  140. Olsen I, Singhrao SK (September 17, 2015). "Can oral infection be a risk factor for Alzheimer's disease?". Journal of Oral Microbiology. 7 29143. doi:10.3402/jom.v7.29143. PMC   4575419 . PMID   26385886.
  141. Carter CJ (February 2011). "Alzheimer's disease plaques and tangles: cemeteries of a pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction". Neurochemistry International. 58 (3): 301–320. doi:10.1016/j.neuint.2010.12.003. PMID   21167244. S2CID   715832.
  142. Vestin E, Boström G, Olsson J, et al. (February 13, 2024). "Herpes Simplex Viral Infection Doubles the Risk of Dementia in a Contemporary Cohort of Older Adults: A Prospective Study". Journal of Alzheimer's Disease. 97 (4): 1841–1850. doi:10.3233/JAD-230718. ISSN   1387-2877. PMC   10894565 . PMID   38306033.
  143. Taylor RA, Gilson A, Chi L, et al. (December 2023). "Dementia risk analysis using temporal event modeling on a large real-world dataset". Sci Rep. 13 (1) 22618. Bibcode:2023NatSR..1322618T. doi:10.1038/s41598-023-49330-8. PMC   10730574 . PMID   38114545.
  144. 1 2 3 Dominguez LJ, Barbagallo M (June 2018). "Nutritional prevention of cognitive decline and dementia". Acta Bio Medica: Atenei Parmensis. 89 (2): 276–290. doi:10.23750/abm.v89i2.7401. PMC   6179018 . PMID   29957766.
  145. Goodman B. "Diet Affects Markers of Alzheimer's Disease". WebMD. Retrieved December 13, 2020.
  146. "Memory loss can be caused by a number of factors, from short term causes such as low blood sugar or medication side effects to long term health issues such as dementia". Diabetes. January 15, 2019. Retrieved December 13, 2020.
  147. Cao L, Tan L, Wang HF, et al. (November 2016). "Dietary Patterns and Risk of Dementia: a Systematic Review and Meta-Analysis of Cohort Studies". Molecular Neurobiology. 53 (9): 6144–6154. doi:10.1007/s12035-015-9516-4. OCLC   6947867710. PMID   26553347. S2CID   8188716.
  148. Canevelli M, Lucchini F, Quarata F, et al. (March 2016). "Nutrition and Dementia: Evidence for Preventive Approaches?". Nutrients. 8 (3). MDPI: 144. doi: 10.3390/nu8030144 . OCLC   8147564576. PMC   4808873 . PMID   26959055.
  149. Shannon OM, Ranson JM, Gregory S, et al. (March 2023). "Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study". BMC Med. 21 (1) 81. doi: 10.1186/s12916-023-02772-3 . PMC   10012551 . PMID   36915130. S2CID   257499227.
  150. Omar SH (June 2019). "Mediterranean and MIND Diets Containing Olive Biophenols Reduces the Prevalence of Alzheimer's Disease". Int J Mol Sci. 20 (11): 2797. doi: 10.3390/ijms20112797 . PMC   6600544 . PMID   31181669.
  151. Makhlouf S, Messelmani M, Zaouali J, et al. (2018). "Cognitive impairment in celiac disease and non-celiac gluten sensitivity: review of literature on the main cognitive impairments, the imaging and the effect of gluten free diet". Acta Neurol Belg (Review). 118 (1): 21–27. doi:10.1007/s13760-017-0870-z. PMID   29247390. S2CID   3943047.
  152. Firth J, Teasdale SB, Allott K, et al. (October 2019). "The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials". World Psychiatry. 18 (3): 308–324. doi:10.1002/wps.20672. PMC   6732706 . PMID   31496103.
  153. Hafdi M, Hoevenaar-Blom MP, Richard E (November 2021). "Multi-domain interventions for the prevention of dementia and cognitive decline". The Cochrane Database of Systematic Reviews. 2021 (11) CD013572. doi:10.1002/14651858.CD013572.pub2. PMC   8574768 . PMID   34748207. S2CID   243846602.
  154. Watt JA, Goodarzi Z, Veroniki AA, et al. (November 2019). "Comparative Efficacy of Interventions for Aggressive and Agitated Behaviors in Dementia: A Systematic Review and Network Meta-analysis". Annals of Internal Medicine. 171 (9): 633–642. doi:10.7326/M19-0993. PMID   31610547. S2CID   204699972.
  155. Vandepitte S, Van Den Noortgate N, Putman K, et al. (December 2016). "Effectiveness of respite care in supporting informal caregivers of persons with dementia: a systematic review". International Journal of Geriatric Psychiatry. 31 (12): 1277–1288. doi:10.1002/gps.4504. PMID   27245986. S2CID   3464912.
  156. Forbes D, Forbes SC, Blake CM, et al. (April 2015). "Exercise programs for people with dementia". The Cochrane Database of Systematic Reviews (Submitted manuscript). 132 (4) CD006489. doi:10.1002/14651858.CD006489.pub4. PMC   9426996 . PMID   25874613.
  157. Crowther G, Dunning R, Russell G, et al. (July 1, 2024). "Dementia in-patient units in psychiatric hospitals: research priority setting". BJPsych Bulletin. 49 (4): 228–234. doi: 10.1192/bjb.2024.42 . ISSN   2056-4694. PMC   12314415 . PMID   38949259.
  158. Wolverson E, Dunning R, Crowther G, et al. (October 19, 2024). "The Characteristics and Outcomes of People with Dementia in Inpatient Mental Health Care: A Review". Clinical Gerontologist. 47 (5): 684–703. doi:10.1080/07317115.2022.2104145. ISSN   0731-7115. PMID   35897148.
  159. 1 2 3 4 Walsh SC, Murphy E, Devane D, et al. (September 2021). "Palliative care interventions in advanced dementia". The Cochrane Database of Systematic Reviews. 2021 (9) CD011513. doi:10.1002/14651858.CD011513.pub3. PMC   8478014 . PMID   34582034.
  160. Camp CJ (2010). "Origins of Montessori Programming for Dementia". Non-pharmacological Therapies in Dementia. 1 (2): 163–174. PMC   3600589 . PMID   23515663.
  161. Cheong CY, Tan JA, Foong YL, et al. (2016). "Creative Music Therapy in an Acute Care Setting for Older Patients with Delirium and Dementia". Dementia and Geriatric Cognitive Disorders Extra. 6 (2): 268–275. doi:10.1159/000445883. PMC   4959431 . PMID   27489560.
  162. Jeon YH, Li Z, Low LF, et al. (August 2015). "The clinical utility of the Cornell Scale for Depression in Dementia as a routine assessment in nursing homes". The American Journal of Geriatric Psychiatry. 23 (8): 784–793. doi:10.1016/j.jagp.2014.08.013. PMID   25256214.
  163. Jeon YH, Liu Z, Li Z, et al. (November 2016). "Development and Validation of a Short Version of the Cornell Scale for Depression in Dementia for Screening Residents in Nursing Homes". The American Journal of Geriatric Psychiatry. 24 (11): 1007–1016. doi:10.1016/j.jagp.2016.05.012. hdl: 1959.4/unsworks_39417 . PMID   27538349.
  164. Harper AE, Rouch S, Leland NE, et al. (April 2022). "A Systematic Review of Tools Assessing the Perspective of Caregivers of Residents With Dementia". Journal of Applied Gerontology. 41 (4): 1196–1208. doi:10.1177/07334648211028692. PMID   34229505. S2CID   235758241.
  165. "The WHELD programme for people with dementia helps care home staff deliver person-centred care" . NIHR Evidence (Plain English summary). November 26, 2020. doi:10.3310/alert_42713. S2CID   240719455.
  166. Ballard C, Orrell M, Moniz-Cook E, et al. (July 2020). "Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs". Programme Grants for Applied Research. 8 (6): 1–98. doi: 10.3310/pgfar08060 . PMID   32721145. S2CID   225489651.
  167. Woods B, O'Philbin L, Farrell EM, et al. (March 2018). "Reminiscence therapy for dementia". The Cochrane Database of Systematic Reviews. 2018 (3) CD001120. doi:10.1002/14651858.CD001120.pub3. PMC   6494367 . PMID   29493789.
  168. Vernooij-Dassen M, Draskovic I, McCleery J, et al. (November 2011). "Cognitive reframing for carers of people with dementia". The Cochrane Database of Systematic Reviews (11) CD005318. arXiv: 0706.4406 . doi:10.1002/14651858.CD005318.pub2. hdl:2066/97731. PMC   12536931 . PMID   22071821. S2CID   205178315.
  169. Neal M, Barton Wright P (2003). "Validation therapy for dementia". The Cochrane Database of Systematic Reviews (3) CD001394. doi:10.1002/14651858.CD001394. PMID   12917907.
  170. Woods B, Aguirre E, Spector AE, et al. (February 2012). "Cognitive stimulation to improve cognitive functioning in people with dementia". The Cochrane Database of Systematic Reviews. 2 (2) CD005562. doi:10.1002/14651858.CD005562.pub2. PMID   22336813. S2CID   7086782.
  171. 1 2 Möhler R, Renom A, Renom H, et al. (August 2020). "Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings". The Cochrane Database of Systematic Reviews. 2020 (8) CD010515. doi:10.1002/14651858.CD010515.pub2. PMC   8094398 . PMID   32786083.
  172. Barker P (2003). Psychiatric and mental health nursing: the craft of caring. London: Arnold. ISBN   978-0-340-81026-2. OCLC   53373798.
  173. Weitzel T, Robinson S, Barnes MR, et al. (2011). "The special needs of the hospitalized patient with dementia". Medsurg Nursing. 20 (1): 13–18, quiz 19. PMID   21446290.
  174. 1 2 Dyer SM, Harrison SL, Laver K, et al. (March 2018). "An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia". International Psychogeriatrics. 30 (3): 295–309. doi: 10.1017/S1041610217002344 . hdl: 2328/38234 . PMID   29143695.
  175. van der Steen JT, van der Wouden JC, Methley AM, et al. (March 7, 2025). "Music-based therapeutic interventions for people with dementia". The Cochrane Database of Systematic Reviews. 2025 (3) CD003477. doi:10.1002/14651858.CD003477.pub5. ISSN   1469-493X. PMC  11884930. PMID   40049590.
  176. Osman SE, Tischler V, Schneider J (November 2016). "'Singing for the Brain': A qualitative study exploring the health and well-being benefits of singing for people with dementia and their carers". Dementia. 15 (6): 1326–1339. doi:10.1177/1471301214556291. PMC   5089222 . PMID   25425445.
  177. 1 2 3 Johnston B, Narayanasamy M (April 2016). "Exploring psychosocial interventions for people with dementia that enhance personhood and relate to legacy – an integrative review". BMC Geriatrics. 16 77. doi: 10.1186/s12877-016-0250-1 . PMC   4820853 . PMID   27044417.
  178. "British hospitals are having a dementia-friendly makeover". The Economist. Retrieved September 19, 2018.
  179. 1 2 Raj SE, Mackintosh S, Fryer C, et al. (January 1, 2021). "Home-Based Occupational Therapy for Adults With Dementia and Their Informal Caregivers: A Systematic Review". The American Journal of Occupational Therapy. 75 (1): 7501205060p1–7501205060p27. doi:10.5014/ajot.2020.040782. PMID   33399054. S2CID   230618534.
  180. 1 2 Frankenstein LL, Jahn G (April 20, 2020). "Behavioral and Occupational Therapy for Dementia Patients and Caregivers" . GeroPsych. 33 (2): 85–100. doi:10.1024/1662-9647/a000225. ISSN   1662-9647. S2CID   219081899.
  181. Orgeta V, McDonald KR, Poliakoff E, et al. (February 2020). "Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease". Cochrane Database of Systematic Reviews. 2020 (2) CD011961. doi:10.1002/14651858.cd011961.pub2. PMC   7043362 . PMID   32101639.
  182. Kudlicka A, Martyr A, Bahar-Fuchs A, et al. (June 29, 2023). Cochrane Dementia and Cognitive Improvement Group (ed.). "Cognitive rehabilitation for people with mild to moderate dementia". Cochrane Database of Systematic Reviews. 2023 (6) CD013388. doi:10.1002/14651858.CD013388.pub2. PMC   10310315 . PMID   37389428.
  183. Möhler R, Calo S, Renom A, et al. (March 2023). "Personally tailored activities for improving psychosocial outcomes for people with dementia in long-term care". The Cochrane Database of Systematic Reviews. 2023 (3) CD009812. doi:10.1002/14651858.CD009812.pub3. PMC   10010156 . PMID   36930048.
  184. Bond M, Rogers G, Peters J, et al. (2012). "The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model". Health Technology Assessment. 16 (21): 1–470. doi:10.3310/hta16210. PMC   4780923 . PMID   22541366.
  185. Birks JS, Harvey RJ (June 18, 2018). "Donepezil for dementia due to Alzheimer's disease". The Cochrane Database of Systematic Reviews. 2018 (6) CD001190. doi:10.1002/14651858.CD001190.pub3. ISSN   1469-493X. PMC   6513124 . PMID   29923184.
  186. Birks J (January 2006). Birks JS (ed.). "Cholinesterase inhibitors for Alzheimer's disease". The Cochrane Database of Systematic Reviews. 2016 (1) CD005593. doi:10.1002/14651858.CD005593. PMC   9006343 . PMID   16437532.
  187. Gill SS, Anderson GM, Fischer HD, et al. (May 2009). "Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study". Archives of Internal Medicine. 169 (9): 867–873. doi: 10.1001/archinternmed.2009.43 . PMID   19433698.
  188. Wang K, Alan J, Page AT, et al. (September 2021). "Anticholinergics and clinical outcomes amongst people with pre-existing dementia: A systematic review". Maturitas. 151. Elsevier BV: 1–14. doi:10.1016/j.maturitas.2021.06.004. PMID   34446273.
  189. AMDA – The Society for Post-Acute and Long-Term Care Medicine (February 2014), "Ten Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation , AMDA – The Society for Post-Acute and Long-Term Care Medicine, archived from the original on April 12, 2015, retrieved April 20, 2015
  190. Walker Z, Possin KL, Boeve BF, et al. (October 2015). "Lewy body dementias". Lancet (Review). 386 (10004): 1683–1697. doi:10.1016/S0140-6736(15)00462-6. PMC   5792067 . PMID   26595642.
  191. Boot BP (2015). "Comprehensive treatment of dementia with Lewy bodies". Alzheimers Res Ther (Review). 7 (1) 45. doi: 10.1186/s13195-015-0128-z . PMC   4448151 . PMID   26029267.
  192. Gomperts SN (April 2016). "Lewy body dementias: Dementia with Lewy bodies and Parkinson disease dementia". Continuum (Minneap Minn) (Review). 22 (2 Dementia): 435–463. doi:10.1212/CON.0000000000000309. PMC   5390937 . PMID   27042903.
  193. 1 2 3 4 5 6 7 American Geriatrics Society. "Five Things Physicians and Patients Should Question". Choosing Wisely: An Initiative of the ABIM Foundation. Archived from the original on September 1, 2013. Retrieved August 1, 2013.
  194. American Psychiatric Association (September 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation , American Psychiatric Association, archived from the original on December 3, 2013, retrieved December 30, 2013
  195. "Dementia: assessment, management and support for people living with dementia and their carers | Guidance and guidelines | NICE". NICE. June 20, 2018. Retrieved December 18, 2018.
  196. Dyer SM, Laver K, Pond CD, et al. (December 2016). "Clinical practice guidelines and principles of care for people with dementia in Australia". Australian Family Physician. 45 (12): 884–889. PMID   27903038.
  197. Declercq T, Petrovic M, Azermai M, et al. (March 2013). "Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia" (PDF). The Cochrane Database of Systematic Reviews. 3 (3) CD007726. doi:10.1002/14651858.CD007726.pub2. hdl: 1854/LU-3109108 . PMID   23543555.
  198. "Memantine as a treatment for dementia | Cochrane". www.cochrane.org. Retrieved September 12, 2025.
  199. Raina P, Santaguida P, Ismaila A, et al. (March 2008). "Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline". Annals of Internal Medicine. 148 (5): 379–397. doi: 10.7326/0003-4819-148-5-200803040-00009 . PMID   18316756.
  200. Atri A, Shaughnessy LW, Locascio JJ, et al. (2008). "Long-term course and effectiveness of combination therapy in Alzheimer disease". Alzheimer Disease and Associated Disorders. 22 (3): 209–221. doi:10.1097/WAD.0b013e31816653bc. PMC   2718545 . PMID   18580597.
  201. 1 2 3 4 Kandiah N, Ong PA, Yuda T, et al. (February 2019). "Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761". CNS Neuroscience & Therapeutics. 25 (2): 288–298. doi:10.1111/cns.13095. PMC   6488894 . PMID   30648358.
  202. McKeage K, Lyseng-Williamson KA (2018). "Ginkgo biloba extract EGb 761 in the symptomatic treatment of mild-to-moderate dementia: a profile of its use". Drugs & Therapy Perspectives. 34 (8): 358–366. doi:10.1007/s40267-018-0537-8. PMC   6267544 . PMID   30546253.
  203. Wang M, Peng H, Peng Z, et al. (September 2020). "Efficacy and safety of ginkgo preparation in patients with vascular dementia: A protocol for systematic review and meta-analysis". Medicine. 99 (37) e22209. doi:10.1097/MD.0000000000022209. PMC   7489658 . PMID   32925798.
  204. Jones HE, Joshi A, Shenkin S, et al. (July 2016). "The effect of treatment with selective serotonin reuptake inhibitors in comparison to placebo in the progression of dementia: a systematic review and meta-analysis". Age and Ageing. 45 (4): 448–456. doi: 10.1093/ageing/afw053 . hdl: 20.500.11820/56792c91-31f0-44cb-8ac0-7f50fad8d91e . PMID   27055878.
  205. Dudas R, Malouf R, McCleery J, et al. (Cochrane Dementia and Cognitive Improvement Group) (August 2018). "Antidepressants for treating depression in dementia". The Cochrane Database of Systematic Reviews. 2018 (8) CD003944. doi:10.1002/14651858.CD003944.pub2. PMC   6513376 . PMID   30168578.
  206. Seitz DP, Adunuri N, Gill SS, et al. (February 2011). "Antidepressants for agitation and psychosis in dementia". The Cochrane Database of Systematic Reviews (2) CD008191. doi:10.1002/14651858.CD008191.pub2. PMC   12214452 . PMID   21328305.
  207. Malouf R, Grimley Evans J (October 2008). "Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people". The Cochrane Database of Systematic Reviews (4) CD004514. doi:10.1002/14651858.CD004514.pub2. PMID   18843658.
  208. McGuinness B, Craig D, Bullock R, et al. (January 2016). "Statins for the prevention of dementia". Cochrane Database Syst Rev. 2016 (1) CD003160. doi:10.1002/14651858.CD003160.pub3. PMC   9346344 . PMID   26727124.
  209. Jongstra S, Harrison JK, Quinn TJ, et al. (November 2016). "Antihypertensive withdrawal for the prevention of cognitive decline". The Cochrane Database of Systematic Reviews. 2016 (11) CD011971. doi:10.1002/14651858.CD011971.pub2. PMC   6465000 . PMID   27802359.
  210. Page AT, Potter K, Clifford R, et al. (October 2016). "Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel". Internal Medicine Journal. 46 (10): 1189–1197. doi:10.1111/imj.13215. PMC   5129475 . PMID   27527376.
  211. Wang K, Alan J, Page A, et al. (2018). "Medication use to manage comorbidities for people with dementia: a systematic review". Journal of Pharmacy Practice and Research. 48 (4): 356–367. doi: 10.1002/jppr.1403 . ISSN   2055-2335.
  212. "Palliative care". World Health Organization (WHO). August 5, 2020. Retrieved April 19, 2025.
  213. Van den Block L (October 2014). "The need for integrating palliative care in ageing and dementia policies". European Journal of Public Health. 24 (5): 705–706. doi: 10.1093/eurpub/cku084 . PMID   24997202.
  214. Nakanishi M, Martins Pereira S, Van den Block L, et al. (May 2024). "Future policy and research for advance care planning in dementia: consensus recommendations from an international Delphi panel of the European Association for Palliative Care". Lancet Healthy Longev. 5 (5): e370–e378. doi:10.1016/S2666-7568(24)00043-6. PMC   11262782 . PMID   38608695.
  215. de Sola-Smith K, Gilissen J, van der Steen JT, et al. (July 4, 2024). "Palliative Care in Early Dementia". Journal of Pain and Symptom Management. 68 (3): e206–e227. doi:10.1016/j.jpainsymman.2024.05.028. PMC   12060741 . PMID   38848792.
  216. Senderovich H, Retnasothie S (November 18, 2019). "A systematic review of the integration of palliative care in dementia management" . Palliative and Supportive Care. 18 (4): 495–506. doi:10.1017/S1478951519000968. ISSN   1478-9515. PMID   31736452.
  217. Walsh SC, Murphy E, Devane D, et al. (September 28, 2021). Cochrane Dementia and Cognitive Improvement Group (ed.). "Palliative care interventions in advanced dementia". Cochrane Database of Systematic Reviews. 2021 (9) CD011513. doi:10.1002/14651858.CD011513.pub3. PMC   8478014 . PMID   34582034.
  218. Vieira Silva S, Conceição P, Antunes B, et al. (January 27, 2025). "Emergency department use and responsiveness to the palliative care needs of patients with dementia at the end of life: A scoping review". Palliative and Supportive Care. 23 e51. doi: 10.1017/S1478951524001627 . ISSN   1478-9515. PMID   39865850.
  219. Williamson LE, Evans CJ, Cripps RL, et al. (July 14, 2021). "Factors Associated With Emergency Department Visits by People With Dementia Near the End of Life: A Systematic Review". Journal of the American Medical Directors Association. 22 (10): 2046–2055.e35. doi: 10.1016/j.jamda.2021.06.012 . PMID   34273269.
  220. 1 2 Miranda R, Bunn F, Lynch J, et al. (May 6, 2019). "Palliative care for people with dementia living at home: A systematic review of interventions". Palliative Medicine. 33 (7): 726–742. doi:10.1177/0269216319847092. ISSN   0269-2163. PMC   6620864 . PMID   31057088.
  221. 1 2 Mataqi M, Aslanpour Z (May 27, 2020). "Factors influencing palliative care in advanced dementia: a systematic review". BMJ Supportive & Palliative Care. 10 (2): 145–156. doi:10.1136/bmjspcare-2018-001692. hdl: 2299/21347 . ISSN   2045-435X. PMID   30944119.
  222. Mo L, Geng Y, Chang YK, et al. (March 2, 2021). "Referral criteria to specialist palliative care for patients with dementia: A systematic review". Journal of the American Geriatrics Society. 69 (6): 1659–1669. doi:10.1111/jgs.17070. ISSN   0002-8614. PMC   8211371 . PMID   33655535.
  223. Erel M, Marcus EL, Dekeyser-Ganz F (October 1, 2017). "Barriers to palliative care for advanced dementia: a scoping review". Annals of Palliative Medicine. 6 (4): 365–379. doi: 10.21037/apm.2017.06.13 . PMID   28754048.
  224. 1 2 Fazio S, Pace D, Flinner J, et al. (January 18, 2018). "The Fundamentals of Person-Centered Care for Individuals With Dementia". The Gerontologist. 58 (suppl_1): S10–S19. doi:10.1093/geront/gnx122. ISSN   0016-9013. PMID   29361064.
  225. Mitchell G, Agnelli J (October 2015). "Person-centred care for people with dementia: Kitwood reconsidered". Nursing Standard. 30 (7): 46–50. doi:10.7748/ns.30.7.46.s47. PMID   26463810.
  226. Kim SK, Park M (February 17, 2017). "Effectiveness of person-centered care on people with dementia: a systematic review and meta-analysis". Clinical Interventions in Aging. 12: 381–397. doi: 10.2147/CIA.S117637 . PMC   5322939 . PMID   28255234.
  227. Barbosa A, Sousa L, Nolan M, et al. (2015). "Effects of Person-Centered Care Approaches to Dementia Care on Staff: A Systematic Review". American Journal of Alzheimer's Disease & Other Dementias. 30 (8): 713–722. doi:10.1177/1533317513520213. ISSN   1533-3175. PMC   10852733 . PMID   24449039.
  228. 1 2 3 Aworinde J, Ellis-Smith C, Gillam J, et al. (January 2022). "How do person-centered outcome measures enable shared decision-making for people with dementia and family carers?—A systematic review". Alzheimer's & Dementia: Translational Research & Clinical Interventions. 8 (1) e12304. doi:10.1002/trc2.12304. ISSN   2352-8737. PMC   9169867 . PMID   35676942.
  229. 1 2 Chen L, Sleeman KE, Bradshaw A, et al. (August 2024). "The Use of Person-Centered Outcome Measures to Support Integrated Palliative Care for Older People: A Systematic Review". Journal of the American Medical Directors Association. 25 (8) 105036. doi: 10.1016/j.jamda.2024.105036 . PMID   38796168.
  230. on behalf of BuildCARE, Ellis-Smith C, Evans CJ, et al. (December 2016). "Measures to assess commonly experienced symptoms for people with dementia in long-term care settings: a systematic review". BMC Medicine. 14 (1): 38. doi: 10.1186/s12916-016-0582-x . ISSN   1741-7015. PMC   4769567 . PMID   26920369.
  231. Felton N, Lewis JS, Cockburn SJ, et al. (October 19, 2021). "Pain Assessment for Individuals with Advanced Dementia in Care Homes: A Systematic Review". Geriatrics. 6 (4): 101. doi: 10.3390/geriatrics6040101 . ISSN   2308-3417. PMC   8544573 . PMID   34698157.
  232. Ellis-Smith C, Evans CJ, Murtagh FE, et al. (July 2017). "Development of a caregiver-reported measure to support systematic assessment of people with dementia in long-term care: The Integrated Palliative care Outcome Scale for Dementia". Palliative Medicine. 31 (7): 651–660. doi:10.1177/0269216316675096. ISSN   0269-2163. PMID   28618899.
  233. 1 2 3 Wilfling D, Calo S, Dichter MN, et al. (January 2023). "Non-pharmacological interventions for sleep disturbances in people with dementia". The Cochrane Database of Systematic Reviews. 1 (1) CD011881. doi:10.1002/14651858.CD011881.pub2. PMC   9808594 . PMID   36594432.
  234. 1 2 3 4 McCleery J, Sharpley AL (November 2020). "Pharmacotherapies for sleep disturbances in dementia". The Cochrane Database of Systematic Reviews. 2020 (11) CD009178. doi:10.1002/14651858.CD009178.pub4. PMC   8094738 . PMID   33189083.
  235. American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–631. doi:10.1111/j.1532-5415.2012.03923.x. PMC   3571677 . PMID   22376048.
  236. Tisher A, Salardini A (April 2019). "A Comprehensive Update on Treatment of Dementia". Seminars in Neurology. 39 (2): 167–178. doi:10.1055/s-0039-1683408. PMID   30925610. S2CID   88474685.
  237. Lolk A, Gulmann NC (October 2006). "[Psychopharmacological treatment of behavioral and psychological symptoms in dementia]". Ugeskrift for Laeger (in Danish). 168 (40): 3429–3432. PMID   17032610.
  238. 1 2 3 4 5 Hadjistavropoulos T, Herr K, Turk DC, et al. (January 2007). "An interdisciplinary expert consensus statement on assessment of pain in older persons". The Clinical Journal of Pain. 23 (1 Suppl): S1–S43. doi:10.1097/AJP.0b013e31802be869. PMID   17179836. S2CID   43777445.
  239. 1 2 Shega J, Emanuel L, Vargish L, et al. (May 2007). "Pain in persons with dementia: complex, common, and challenging". The Journal of Pain. 8 (5): 373–378. doi: 10.1016/j.jpain.2007.03.003 . PMID   17485039.
  240. Blyth FM, Cumming R, Mitchell P, et al. (July 2007). "Pain and falls in older people". European Journal of Pain. 11 (5): 564–571. doi:10.1016/j.ejpain.2006.08.001. PMID   17015026. S2CID   27460864.
  241. Brown C (2009). "Pain, aging and dementia: The crisis is looming, but are we ready?". British Journal of Occupational Therapy. 72 (8): 371–375. doi:10.1177/030802260907200808. S2CID   73245194.
  242. Herr K, Bjoro K, Decker S (February 2006). "Tools for assessment of pain in nonverbal older adults with dementia: a state-of-the-science review". Journal of Pain and Symptom Management. 31 (2): 170–192. doi: 10.1016/j.jpainsymman.2005.07.001 . PMID   16488350.
  243. Stolee P, Hillier LM, Esbaugh J, et al. (February 2005). "Instruments for the assessment of pain in older persons with cognitive impairment". Journal of the American Geriatrics Society. 53 (2): 319–326. doi:10.1111/j.1532-5415.2005.53121.x. PMID   15673359. S2CID   21006144.
  244. AMDA – The Society for Post-Acute and Long-Term Care Medicine (February 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation , AMDA – The Society for Post-Acute and Long-Term Care Medicine, archived from the original on September 13, 2014, retrieved February 10, 2013
  245. "Patient decision aid on enteral (tube) feeding for people living with severe dementia". National Institute for Health and Care Excellence (NICE). Retrieved April 16, 2025.
  246. AMDA – The Society for Post-Acute and Long-Term Care Medicine (February 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation , AMDA – The Society for Post-Acute and Long-Term Care Medicine, archived from the original on September 13, 2014, retrieved February 10, 2013, which cites:
  247. Mitchell SL, Kiely DK, Lipsitz LA (February 1997). "The risk factors and impact on survival of feeding tube placement in nursing home residents with severe cognitive impairment". Archives of Internal Medicine. 157 (3): 327–332. doi:10.1001/archinte.1997.00440240091014. PMID   9040301.
  248. Sampson EL, Candy B, Jones L (April 2009). "Enteral tube feeding for older people with advanced dementia". The Cochrane Database of Systematic Reviews. 2009 (2) CD007209. doi:10.1002/14651858.CD007209.pub2. PMC   7182132 . PMID   19370678.
  249. Lockett MA, Templeton ML, Byrne TK, et al. (February 2002). "Percutaneous endoscopic gastrostomy complications in a tertiary-care center". The American Surgeon. 68 (2): 117–120. doi:10.1177/000313480206800202. PMID   11842953. S2CID   43796062.
  250. Finocchiaro C, Galletti R, Rovera G, et al. (June 1997). "Percutaneous endoscopic gastrostomy: a long-term follow-up". Nutrition. 13 (6): 520–523. doi:10.1016/S0899-9007(97)00030-0. PMID   9263232.
  251. Mitchell SL, Mor V, Gozalo PL, et al. (August 2016). "Tube Feeding in US Nursing Home Residents With Advanced Dementia, 2000–2014" (PDF). JAMA. 316 (7): 769–770. doi:10.1001/jama.2016.9374. PMC   4991625 . PMID   27533163. Archived (PDF) from the original on September 21, 2017.
  252. Span P (August 29, 2016). "The Decline of Tube Feeding for Dementia Patients". The New York Times . Archived from the original on September 3, 2016. Retrieved August 31, 2016.
  253. 1 2 Flynn E, Smith CH, Walsh CD, et al. (September 2018). "Modifying the consistency of food and fluids for swallowing difficulties in dementia". The Cochrane Database of Systematic Reviews. 2018 (9) CD011077. doi:10.1002/14651858.cd011077.pub2. PMC   6513397 . PMID   30251253.
  254. Forbes D, Forbes SC, Blake CM, et al. (April 2015). "Exercise programs for people with dementia". The Cochrane Database of Systematic Reviews. 2015 (4) CD006489. doi:10.1002/14651858.CD006489.pub4. PMC   9426996 . PMID   25874613.
  255. Smith M, Robinson L, Segal J (November 2, 2018). "Preventing Alzheimer's Disease – HelpGuide.org". HelpGuide.org. Retrieved December 13, 2020.
  256. Van der Roest HG, Wenborn J, Pastink C, et al. (June 2017). "Assistive technology for memory support in dementia". The Cochrane Database of Systematic Reviews. 2017 (6) CD009627. doi:10.1002/14651858.cd009627.pub2. PMC   6481376 . PMID   28602027.
  257. "7 Technological Innovations for Those With Dementia". Alzheimers.net. Retrieved June 28, 2022.
  258. Meek H, Rooker S, Malik H, et al. (February 17, 2025). "Inclusive Futures: Harnessing Virtual Reality for Dementia Care". eprints.whiterose.ac.uk. doi:10.48785/100/313 . Retrieved March 5, 2025.
  259. Anderson M, Menon R, Oak K, et al. (June 2022). "The use of technology for social interaction by people with dementia: A scoping review". PLOS Digital Health. 1 (6) e0000053. doi: 10.1371/journal.pdig.0000053 . PMC   9931370 . PMID   36812560.
  260. Pappadà A, Chattat R, Chirico I, et al. (March 24, 2021). "Assistive Technologies in Dementia Care: An Updated Analysis of the Literature". Frontiers in Psychology. 12 644587. doi: 10.3389/fpsyg.2021.644587 . ISSN   1664-1078. PMC   8024695 . PMID   33841281.
  261. 1 2 3 Yi JS, Pittman CA, Price CL, et al. (April 19, 2021). "Telemedicine and Dementia Care: A Systematic Review of Barriers and Facilitators". Journal of the American Medical Directors Association. 22 (7): 1396–1402.e18. doi:10.1016/j.jamda.2021.03.015. PMC   8292189 . PMID   33887231.
  262. 1 2 González-Fraile E, Ballesteros J, Rueda JR, et al. (January 2021). "Remotely delivered information, training and support for informal caregivers of people with dementia". The Cochrane Database of Systematic Reviews. 1 (1) CD006440. doi:10.1002/14651858.cd006440.pub3. PMC   8094510 . PMID   33417236.
  263. Dooley B, Ueno H (February 2, 2022). "Where a Thousand Digital Eyes Keep Watch Over the Elderly". The New York Times. ISSN   0362-4331 . Retrieved February 6, 2022.
  264. Viggo Hansen N, Jørgensen T, Ørtenblad L (October 2006). "Massage and touch for dementia". The Cochrane Database of Systematic Reviews. 2006 (4) CD004989. doi:10.1002/14651858.CD004989.pub2. PMC   6823223 . PMID   17054228.
  265. Ball EL, Owen-Booth B, Gray A, et al. (August 2020). "Aromatherapy for dementia". The Cochrane Database of Systematic Reviews. 2020 (8) CD003150. doi:10.1002/14651858.CD003150.pub3. PMC   7437395 . PMID   32813272.
  266. Bosnjak Kuharic D, Markovic D, Brkovic T, et al. (September 2021). "Cannabinoids for the treatment of dementia". The Cochrane Database of Systematic Reviews. 2021 (9) CD012820. doi:10.1002/14651858.CD012820.pub2. PMC   8446835 . PMID   34532852.
  267. "The top 10 causes of death". www.who.int. Retrieved August 12, 2024.
  268. Nichols E, Steinmetz JD, Vollset SE, et al. (GBD 2019 Dementia Forecasting Collaborators) (February 2022). "Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019". The Lancet. Public Health. 7 (2): e105–e125. doi:10.1016/S2468-2667(21)00249-8. PMC   8810394 . PMID   34998485.
  269. Sleeman KE, de Brito M, Etkind S, et al. (May 22, 2019). "The escalating global burden of serious health-related suffering: projections to 2060 by world regions, age groups, and health conditions". The Lancet Global Health. 7 (7): e883–e892. doi:10.1016/S2214-109X(19)30172-X. PMC   6560023 . PMID   31129125.
  270. 1 2 3 4 5 6 Alzheimer's Disease International (September 2015). "World Alzheimer Report 2015" (PDF). Archived (PDF) from the original on October 9, 2022. Retrieved October 30, 2018.
  271. "The economic impact of dementia" (PDF). Alzheimer's Society. May 2024.
  272. 1 2 Sadock BJ, Sadock VA (2008). "Delirium, Dementia, and Amnestic and Other Cobnitive Disorders and Mental Disorders Due to a General Medical Condition". Kaplan & Sadock's concise textbook of clinical psychiatry (3rd ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 52. ISBN   978-0-7817-8746-8.
  273. Ali M, Talha M, Naseer B, et al. (August 13, 2024). "Divergent Mortality Patterns Associated With Dementia in the United States: 1999–2020" . The Primary Care Companion for CNS Disorders. 26 (4): 56364. doi:10.4088/PCC.24m03724. ISSN   2155-7780. PMID   39178013.
  274. Brijnath B, Croy S, Sabates J, et al. (2022). "Including ethnic minorities in dementia research: Recommendations from a scoping review". Alzheimer's & Dementia. 8 (1) e12222. doi:10.1002/trc2.12222. PMC   9053375 . PMID   35505899.
  275. Sabayan B, Wyman-Chick KA, Sedaghat S (February 2023). "The Burden of Dementia Spectrum Disorders and Associated Comorbid and Demographic Features". Clinics in Geriatric Medicine. 39 (1): 1–14. doi:10.1016/j.cger.2022.07.001. PMID   36404023. S2CID   253068389.
  276. Ariana M. Stickel, Andrew C. McKinnon, Stephanie Matijevik, et al. (February 26, 2021). "Apolipoprotein E ε4 Allele-Based Differences in Brain Volumes Are Largely Uniform Across Late Middle Aged and Older Hispanic/Latino- and Non-Hispanic/Latino Whites Without Dementia". Frontiers in Aging Neuroscience. 13 627322. doi: 10.3389/fnagi.2021.627322 . PMC   7952627 . PMID   33716715.
  277. Thompson D (May 29, 2025). "Dementia Tied To Heart, Metabolic Diseases". www.healthday.com. Retrieved June 1, 2025.
  278. Karway GK, Krzyzanowski B, Killion JA, et al. (2025). "Regional variability of the impact of cardiometabolic diseases on incident dementia in United States Medicare beneficiaries". Alzheimer's & Dementia. 21 (5) e70199. doi:10.1002/alz.70199. ISSN   1552-5279. PMC   12100501 . PMID   40407074.
  279. 1 2 "Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding". Office of Health Economics (OHE). June 26, 2024. Retrieved April 19, 2025.
  280. Jacobsohn GC, Hollander M, Beck AP, et al. (January 9, 2019). "Factors Influencing Emergency Care by Persons With Dementia: Stakeholder Perceptions and Unmet Needs". Journal of the American Geriatrics Society. 67 (4): 711–718. doi:10.1111/jgs.15737. ISSN   0002-8614. PMC   6458085 . PMID   30624765.
  281. Bamford C, Wheatley A, Brunskill G, et al. (December 20, 2021). Shahabi S (ed.). "Key components of post-diagnostic support for people with dementia and their carers: A qualitative study". PLOS ONE. 16 (12) e0260506. Bibcode:2021PLoSO..1660506B. doi: 10.1371/journal.pone.0260506 . ISSN   1932-6203. PMC   8687564 . PMID   34928972.
  282. Wei G, McDonald S, Kelly M, et al. (April 24, 2025). "Post-diagnostic care pathways in dementia: Experiences and needs of family carers and considerations for interventions". Dementia 14713012251337230. doi: 10.1177/14713012251337230 . ISSN   1471-3012. PMID   40272843.
  283. Williamson LE, Sleeman KE, Evans CJ (July 24, 2023). "Exploring access to community care and emergency department use among people with dementia: A qualitative interview study with people with dementia, and current and bereaved caregivers". International Journal of Geriatric Psychiatry. 38 (7) e5966. doi:10.1002/gps.5966. ISSN   0885-6230. PMID   37485729.
  284. Dooley J, Webb J, James R, et al. (January 28, 2025). "Exploring experiences of dementia post-diagnosis support and ideas for improving practice: A co-produced study" . Dementia. 24 (7) 14713012241312845. doi:10.1177/14713012241312845. ISSN   1471-3012. PMID   39876088.
  285. Harrison KL, Hunt LJ, Ritchie CS, et al. (March 25, 2019). "Dying With Dementia: Underrecognized and Stigmatized". Journal of the American Geriatrics Society. 67 (8): 1548–1551. doi:10.1111/jgs.15895. ISSN   0002-8614. PMC   6684346 . PMID   30908605.
  286. Giebel C (August 14, 2024). "A new model to understand the complexity of inequalities in dementia". International Journal for Equity in Health. 23 (1) 160. doi: 10.1186/s12939-024-02245-w . ISSN   1475-9276. PMC   11323611 . PMID   39138491.
  287. Best Rogowski CB, Bredell C, Shi Y, et al. (July 2025). "Long-term air pollution exposure and incident dementia: a systematic review and meta-analysis". The Lancet Planetary Health. 9 (7): 101266. doi: 10.1016/S2542-5196(25)00118-4 . PMID   40716448.
  288. Giebel C, Readman MR, Godfrey A, et al. (February 21, 2025). "Geographical inequalities in dementia diagnosis and care: A systematic review". International Psychogeriatrics. 37 (3) 100051. doi: 10.1016/j.inpsyc.2025.100051 . PMC   12149024 . PMID   39986949.
  289. Godard-Sebillotte C, Arsenault-Lapierre G, Sourial N, et al. (March 2025). "Examining equity in service use across socioeconomic status in people with dementia". Alzheimer's & Dementia: Behavior & Socioeconomics of Aging. 1 (1) e70006. doi: 10.1002/bsa3.70006 . ISSN   2997-3805.
  290. 1 2 Williamson LE, Leniz J, Chukwusa E, et al. (March 1, 2023). "A population-based retrospective cohort study of end-of-life emergency department visits by people with dementia: multilevel modelling of individual- and service-level factors using linked data". Age and Ageing. 52 (3) afac332. doi:10.1093/ageing/afac332. ISSN   0002-0729. PMC   9978317 . PMID   36861183.
  291. Leniz J, Higginson IJ, Stewart R, et al. (September 1, 2019). "Understanding which people with dementia are at risk of inappropriate care and avoidable transitions to hospital near the end-of-life: a retrospective cohort study". Age and Ageing. 48 (5): 672–679. doi: 10.1093/ageing/afz052 . ISSN   0002-0729. PMID   31135024.
  292. Davies JM, Sleeman KE, Leniz J, et al. (April 23, 2019). Prigerson HG (ed.). "Socioeconomic position and use of healthcare in the last year of life: A systematic review and meta-analysis". PLOS Medicine. 16 (4) e1002782. doi: 10.1371/journal.pmed.1002782 . ISSN   1549-1676. PMC   6478269 . PMID   31013279.
  293. Kornblith E, Bahorik A, Boscardin WJ, et al. (April 19, 2022). "Association of Race and Ethnicity With Incidence of Dementia Among Older Adults". JAMA. 327 (15): 1488–1495. doi:10.1001/jama.2022.3550. ISSN   0098-7484. PMC   9020215 . PMID   35438728.
  294. Shiekh SI, Cadogan SL, Lin LY, et al. (March 9, 2021). Ikram MA (ed.). "Ethnic Differences in Dementia Risk: A Systematic Review and Meta-Analysis". Journal of Alzheimer's Disease. 80 (1): 337–355. doi:10.3233/JAD-201209. PMC   8075390 . PMID   33554910.
  295. Luth EA, Prigerson HG (July 2018). "Associations between Race and Dementia Status and the Quality of End-of-Life Care". Journal of Palliative Medicine. 21 (7): 970–977. doi:10.1089/jpm.2017.0638. ISSN   1096-6218. PMC   6034391 . PMID   29620949.
  296. Koffman J (June 2018). Dementia and end of life care for black, Asian and minority ethnic communities (PDF). Better Health Briefing 45. Race Equality Foundation.
  297. Zabihi S, Bestwick JP, Jitlal M, et al. (February 2025). "Early presentations of dementia in a diverse population". Alzheimer's & Dementia. 21 (2) e14578. doi:10.1002/alz.14578. ISSN   1552-5260. PMC   11863067 . PMID   40008622.
  298. "Ethnic minorities experience greater effect of dementia risk factors, study suggests". Alzheimer's Research UK. Retrieved April 19, 2025.
  299. Erol R, Brooker D, Peel E (June 2015). Women and Dementia. A global research review (PDF). Alzheimer's Disease International.
  300. "The Impact of Dementia on Women". Alzheimer's Research UK. Retrieved April 19, 2025.
  301. Wong AD, Phillips SP (January 2023). "Gender Disparities in End of Life Care: A Scoping Review". Journal of Palliative Care. 38 (1): 78–96. doi:10.1177/08258597221120707. ISSN   0825-8597. PMC   9667103 . PMID   35996340.
  302. Berrios GE (November 1987). "Dementia during the seventeenth and eighteenth centuries: a conceptual history". Psychological Medicine. 17 (4): 829–837. doi:10.1017/S0033291700000623. PMID   3324141. S2CID   8262492.
  303. Berchtold NC, Cotman CW (1998). "Evolution in the conceptu-alization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s". Neurobiol Aging. 19 (3): 173–189. doi:10.1016/s0197-4580(98)00052-9. PMID   9661992. S2CID   24808582.
  304. Bergener M, Reisberg B (1989). Diagnosis and treatment of senile dementia. Berlin, Germany: Springer-Verlag. ISBN   0-387-50800-7. OCLC   19455117.
  305. Xihua J (1989). Diagnosis and Treatment of Senile Dementia: Research Methods and Perspective. Madhav Books (P) Limited, a unit of Serials Publications. p. 38. ISBN   93-80615-34-5.
  306. 1 2 3 Zilka, N., & Novak, M. (2006). The tangled story of Alois Alzheimer. Bratislavske lekarske listy, 107(9–10), 343–345.
  307. 1 2 3 4 5 6 7 8 Yang HD, Kim DH, Lee SB, et al. (December 2016). "History of Alzheimer's Disease". Dementia and Neurocognitive Disorders. 15 (4): 115–121. doi:10.12779/dnd.2016.15.4.115. PMC   6428020 . PMID   30906352.
  308. Kolata G (June 17, 2010). "Drug Trials Test Bold Plan to Slow Alzheimer's". The New York Times. Archived from the original on April 9, 2012. Retrieved June 17, 2010.
  309. Katzman R (April 1976). "Editorial: The prevalence and malignancy of Alzheimer disease. A major killer". Archives of Neurology. 33 (4): 217–218. doi:10.1001/archneur.1976.00500040001001. PMID   1259639.
  310. "Prevalence by gender in the UK". Dementia Statistics Hub. Retrieved October 4, 2021.
  311. "The Impact of Dementia on Women". Alzheimer's Research UK. Retrieved January 19, 2025.
  312. Taylor DC. "Dementia". MedicineNet. Retrieved August 6, 2018. Senile dementia ("senility") is a term that was once used to describe all dementias; this term is no longer used as a diagnosis.
  313. "The Relationship Between Schizophrenia and Dementia". Psychology Today. Retrieved December 13, 2020.
  314. Brodaty H, Donkin M (April 29, 2017). "Family caregivers of people with dementia". Dialogues in Clinical Neuroscience. 11 (2): 217–228. doi:10.31887/DCNS.2009.11.2/hbrodaty. PMC   3181916 . PMID   19585957.
  315. "Most people caring for relatives with dementia experience loneliness" . NIHR Evidence (Plain English summary). July 22, 2020. doi:10.3310/alert_40575. S2CID   243269845.
  316. Victor CR, Rippon I, Quinn C, et al. (July 2021). "The prevalence and predictors of loneliness in caregivers of people with dementia: findings from the IDEAL programme". Aging & Mental Health. 25 (7): 1232–1238. doi: 10.1080/13607863.2020.1753014 . hdl: 10454/17813 . PMID   32306759. S2CID   216028843.
  317. 1 2 3 4 Leniz J, Yi D, Yorganci E, et al. (September 14, 2021). "Exploring costs, cost components, and associated factors among people with dementia approaching the end of life: A systematic review". Alzheimer's & Dementia: Translational Research & Clinical Interventions. 7 (1) e12198. doi:10.1002/trc2.12198. ISSN   2352-8737. PMC   8438684 . PMID   34541291.
  318. From plan to impact VIII: Time to deliver (PDF). London: Alzheimer's Disease International. 2025.
  319. 1 2 Jia J, Wei C, Chen S, et al. (April 2018). "The cost of Alzheimer's disease in China and re-estimation of costs worldwide". Alzheimer's & Dementia. 14 (4): 483–491. doi:10.1016/j.jalz.2017.12.006. PMID   29433981. S2CID   46762069.
  320. Mattap SM, Mohan D, McGrattan AM, et al. (April 4, 2022). "The economic burden of dementia in low- and middle-income countries (LMICs): a systematic review". BMJ Global Health. 7 (4) e007409. doi:10.1136/bmjgh-2021-007409. ISSN   2059-7908. PMC   8981345 . PMID   35379735.
  321. Kenne Malaha A, Thébaut C, Achille D, et al. (January 3, 2023). Vandepitte S (ed.). "Costs of Dementia in Low- And Middle-Income Countries: A Systematic Review". Journal of Alzheimer's Disease. 91 (1): 115–128. doi:10.3233/JAD-220239. PMID   36404540.
  322. "ADI - World's largest dementia study reveals two thirds of people still incorrectly think dementia is a normal part of ageing, rather than a medical condition" . Retrieved January 29, 2026.
  323. 1 2 3 4 World Alzheimer Report 2024. Global changes in attitudes to dementia (PDF). London, England: Alzheimer's Disease International. 2024.
  324. Researcher D (December 13, 2022). "9 in 10 of the public underestimate the impact of dementia". Dementia Researcher. Retrieved April 21, 2025.
  325. Williamson LE, Sleeman KE, Evans CJ (July 2023). "Exploring access to community care and emergency department use among people with dementia: A qualitative interview study with people with dementia, and current and bereaved caregivers". International Journal of Geriatric Psychiatry. 38 (7) e5966. doi: 10.1002/gps.5966 . ISSN   0885-6230. PMID   37485729.
  326. "Maria Shriver | My Brain | Alzheimer's Association". My Brain. September 17, 2014. Retrieved April 21, 2025.
  327. "Alzheimer's Association Celebrity Champions". Alzheimer's Association. Retrieved July 19, 2024.
  328. "Willis Family Statement | AFTD". February 13, 2023. Retrieved July 19, 2024.
  329. Rogers K (July 1, 2022). "What Robin Williams' widow wants you to know about the future of Lewy body dementia". CNN. Retrieved July 19, 2024.
  330. Lerner BH (November 20, 2006). "Rita Hayworth's misdiagnosed struggle". Los Angeles Times. Retrieved April 16, 2025.
  331. "Doctor: Rosa Parks suffers from dementia". NBC. September 22, 2004.
  332. "Reagan's Letter Announcing his Alzheimer's Diagnosis". Ronald Reagan. Retrieved July 19, 2024.
  333. "Wendy Williams diagnosed with same form of dementia as Bruce Willis". AP News. February 22, 2024. Retrieved April 16, 2025.
  334. "What to know about Tony Bennett's health struggles, from Alzheimer's to addiction". TODAY.com. July 21, 2023. Retrieved July 19, 2024.
  335. "Maureen McGovern on Living with Alzheimer's Disease: 'You Go One Day at a Time'". Peoplemag. Retrieved July 19, 2024.
  336. "The Irish-American Billionaire Who Gave Away His Fortune | Atlantic Philanthropies". The Atlantic Philanthropies. January 3, 2017. Retrieved January 28, 2026.
  337. Ezra M (October 23, 2020). "Why Are TikTok Teens Listening to an Album About Dementia?" . The New York Times . Archived from the original on October 23, 2020. Retrieved April 21, 2021.
  338. "Paul Harvey: Composer with dementia inspires £1m donation". BBC News. November 2, 2020. Retrieved November 2, 2020.
  339. Javeed A, Dallora AL, Berglund JS, et al. (February 1, 2023). "Machine Learning for Dementia Prediction: A Systematic Review and Future Research Directions". Journal of Medical Systems. 47 (1): 17. doi:10.1007/s10916-023-01906-7. ISSN   1573-689X. PMC   9889464 . PMID   36720727.
  340. "Co-production Toolkit. A guide to working in co-production with people living with dementia" (PDF). EMPOWER Dementia Network+. 2025. Retrieved November 21, 2025.
  341. "The Dementia Enquirers Gold Standards for Co-Research" (PDF). Dementia Enquirers. 2023. Retrieved November 24, 2025.
  342. "The Dementia Enquirers Gold Standards for Ethical Research" (PDF). Dementia Enquirers. 2023. Retrieved November 25, 2025.
  343. Evans CJ, Yorganci E, Lewis P, et al. (July 22, 2020). "Processes of consent in research for adults with impaired mental capacity nearing the end of life: systematic review and transparent expert consultation (MORECare_Capacity statement)". BMC Medicine. 18 (1) 221. doi: 10.1186/s12916-020-01654-2 . ISSN   1741-7015. PMC   7374835 . PMID   32693800.
  344. "EMPOWER Dementia Network+". EMPOWER Dementia Network+. Retrieved November 24, 2025.
  345. "Addressing unequal access to dementia care". King's College London. Retrieved November 24, 2025.

Further reading